1
|
Gomonit MM, Swortwood MJ, Truver MT, Skillman BN. Analysis of N,N-dimethyltryptamine (DMT) and its metabolites using LC-MS/MS for forensic purposes. J Forensic Sci 2025. [PMID: 40090896 DOI: 10.1111/1556-4029.70013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2024] [Revised: 02/05/2025] [Accepted: 02/07/2025] [Indexed: 03/18/2025]
Abstract
Ayahuasca contains N,N-dimethyltryptamine (DMT), the primary alkaloid responsible for its psychedelic effects. DMT oxidative deamination yields indole-3-acetic acid (IAA) as the predominant metabolite, while N-oxidation produces N,N-dimethyltryptamine-N-oxide (DMT-NO) as the second most abundant metabolite. An LC-MS/MS method was developed and validated to quantify DMT, IAA, and DMT-NO in human plasma, as well as DMT and DMT-NO in human urine. Protein precipitation using a 75:25 (v/v) acetonitrile:methanol yielded analyte recoveries ≥91% in both plasma and urine. Key parameters including matrix effects, linearity, bias, precision, stability, carryover, and dilution integrity met their respective acceptability criterion outlined by ANSI/ASB 036 recommendations. In plasma, the linear range was 0.5-500 ng/mL (DMT), 0.25-125 ng/mL (DMT-NO), and 240-6000 ng/mL (IAA), while the DMT and DMT-NO range in urine was 2.5-250 ng/mL. Bias was within ±17.5%, and precision was ≤6.4% in both plasma and urine. Analytes were free from exogenous/endogenous interferences, and carryover was negligible. Extracts were also stable in the autosampler compartment (4°C) for 48 hours. A proof-of-concept study was conducted using authentic paired peripheral blood and urine samples. Results showed higher concentrations of DMT and DMT-NO found in urine as compared to plasma, highlighting the rapid metabolism and clearance of DMT and its metabolites. This study proposes the utility of DMT and DMT-NO as direct and distinctive biomarkers for forensic determination of exogenous DMT consumption. While IAA is the predominant metabolite of DMT, IAA should not be relied upon as the sole biomarker due to its substantial endogenous presence in both plasma and urine.
Collapse
Affiliation(s)
- Munchelou M Gomonit
- Department of Forensic Science, College of Criminal Justice, Sam Houston State University, Huntsville, Texas, USA
| | - Madeleine J Swortwood
- Department of Forensic Science, College of Criminal Justice, Sam Houston State University, Huntsville, Texas, USA
- Robson Forensic, Dublin, Ohio, USA
| | - Michael T Truver
- Department of Pathology, Immunology, and Laboratory Medicine, University of Florida College of Medicine, Gainesville, Florida, USA
| | - Britni N Skillman
- Department of Forensic Science, College of Criminal Justice, Sam Houston State University, Huntsville, Texas, USA
| |
Collapse
|
2
|
Gonçalves J, Rosado T, Barroso M, Restolho J, Fernández N, Luís Â, Gallardo E, Duarte AP. Comparative study of sample preparation procedures to determine the main compounds in ayahuasca beverages by QuEChERS and high-performance liquid chromatography analysis. PHYTOCHEMICAL ANALYSIS : PCA 2024; 35:1371-1382. [PMID: 38699824 DOI: 10.1002/pca.3370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/09/2024] [Revised: 04/12/2024] [Accepted: 04/13/2024] [Indexed: 05/05/2024]
Abstract
INTRODUCTION Ayahuasca is a psychoactive drink originally consumed by indigenous people of the Amazon. The lack of regulation of this drink leads to uncontrolled consumption, and it is often consumed in religious contexts. OBJECTIVE The aim of this work is to compare three miniaturised extraction techniques for extracting the main ayahuasca compounds from beverages. METHODOLOGY Three sample pretreatment techniques were evaluated (dispersive liquid-liquid microextraction [DLLME], microextraction by packed sorbent [MEPS] and QuEChERS [Quick, Easy, Cheap, Effective, Rugged and Safe]) for the simultaneous extraction of N,N-dimethyltryptamine (DMT), tetrahydroharmine (THH), harmine, harmaline, harmol and harmalol from ayahuasca beverage samples. Then, the most promising technique (QuEChERS) was chosen to pre-concentrate the analytes, subsequently detected by high-performance liquid chromatography coupled to a diode array detector (HPLC-DAD). RESULTS The procedure was optimised, with the final conditions being 500 μL of extractor solvent, 85 mg of primary secondary amine (PSA) and 4 s of vortexing. The analytical method was validated, showing to be linear between 0.16 and 10 μg/mL for β-carbolines and between 0.016 and 1 μg/mL for DMT, with coefficients of determination (R2) between 0.9968 and 0.9993. The limit of detection (LOD) and lower limit of quantification (LLOQ) were 0.16 μg/mL for all compounds, except for DMT (0.016 μg/mL) and extraction efficiencies varied between 60.2% and 88.0%. CONCLUSION The analytical methodology proved to be accurate and precise, with good linearity, LODs and LLOQs. This method has been fully validated and successfully applied to ayahuasca beverage samples.
Collapse
Affiliation(s)
- Joana Gonçalves
- Centro de Investigação em Ciências da Saúde (CICS-UBI), Universidade da Beira Interior, Covilhã, Portugal
- Laboratório de Fármaco-Toxicologia, UBIMedical, Universidade da Beira Interior, Covilhã, Portugal
| | - Tiago Rosado
- Centro de Investigação em Ciências da Saúde (CICS-UBI), Universidade da Beira Interior, Covilhã, Portugal
- Laboratório de Fármaco-Toxicologia, UBIMedical, Universidade da Beira Interior, Covilhã, Portugal
| | - Mário Barroso
- Serviço de Química e Toxicologia Forenses, Instituto Nacional de Medicina Legal e Ciências Forenses, Delegação do Sul, Lisbon, Portugal
| | | | - Nicolás Fernández
- Cátedra de Toxicología y Química Legal, Laboratorio de Asesoramiento Toxicológico Analítico (CENATOXA), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
| | - Ângelo Luís
- Centro de Investigação em Ciências da Saúde (CICS-UBI), Universidade da Beira Interior, Covilhã, Portugal
- Laboratório de Fármaco-Toxicologia, UBIMedical, Universidade da Beira Interior, Covilhã, Portugal
| | - Eugenia Gallardo
- Centro de Investigação em Ciências da Saúde (CICS-UBI), Universidade da Beira Interior, Covilhã, Portugal
- Laboratório de Fármaco-Toxicologia, UBIMedical, Universidade da Beira Interior, Covilhã, Portugal
| | - Ana Paula Duarte
- Centro de Investigação em Ciências da Saúde (CICS-UBI), Universidade da Beira Interior, Covilhã, Portugal
- Laboratório de Fármaco-Toxicologia, UBIMedical, Universidade da Beira Interior, Covilhã, Portugal
| |
Collapse
|
3
|
Lauria PSS, Gomes JDM, Abreu LS, Santana RC, Nunes VLC, Couto RD, Colavolpe PO, Silva MSD, Soares MBP, Villarreal CF. Ayahuasca and its major component harmine promote antinociceptive effects in mouse models of acute and chronic pain. JOURNAL OF ETHNOPHARMACOLOGY 2024; 323:117710. [PMID: 38184028 DOI: 10.1016/j.jep.2024.117710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 12/20/2023] [Accepted: 01/02/2024] [Indexed: 01/08/2024]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Ayahuasca (AYA) is a psychedelic brew used in religious ceremonies. It is broadly used as a sacred medicine for treating several ailments, including pain of various origins. AIM OF THE STUDY To investigate the antinociceptive effects of AYA and its mechanisms in preclinical models of acute and chronic pain in mice, in particular during experimental neuropathy. MATERIALS AND METHODS The antinociceptive effects of AYA administered orally were assessed in the following models of pain: formalin test, Complete Freund's Adjuvant (CFA)-induced inflammation, tail flick test, and partial sciatic nerve ligation model of neuropathic pain. Antagonism assays and Fos immunohistochemistry in the brain were performed. AYA-induced toxicity was investigated. AYA was chemically characterized. The antinociceptive effect of harmine, the major component present in AYA, was investigated. RESULTS AYA (24-3000 μL/kg) dose-dependently reduced formalin-induced pain-like behaviors and CFA-induced mechanical allodynia but did not affect CFA-induced paw edema or tail flick latency. During experimental neuropathy, single treatments with AYA (24-3000 μL/kg) reduced mechanical allodynia; daily treatments once or twice a day for 14 days promoted consistent and sustained antinociception. The antinociceptive effect of AYA (600 μL/kg) was reverted by bicuculline (1 mg/kg) and methysergide (5 mg/kg), but not by naloxone (5 mg/kg), phaclofen (2 mg/kg), and rimonabant (10 mg/kg), suggesting the roles of GABAA and serotonergic receptors. AYA increased Fos expression in the ventrolateral periaqueductal gray and nucleus raphe magnus after 1 h, but not after 6 h or 14 days of daily treatments. AYA (600 μL/kg) twice a day for 14 days did not alter mice's motor function, spontaneous locomotion, body weight, food and water intake, hematological, biochemical, and histopathological parameters. Harmine (3.5 mg/kg) promoted consistent antinociception during experimental neuropathy. CONCLUSIONS AYA promotes consistent antinociceptive effects in different mouse models of pain without inducing detectable toxic effects. Harmine is at least partially accountable for the antinociceptive properties of AYA.
Collapse
Affiliation(s)
| | - Juliana de Medeiros Gomes
- Department of Pharmaceutical Sciences, Federal University of Paraíba, 58.050-585, João Pessoa, PB, Brazil.
| | - Lucas Silva Abreu
- Chemistry Institute, Fluminense Federal University, 24.020-150, Niterói, RJ, Brazil.
| | | | | | - Ricardo David Couto
- School of Pharmacy, Federal University of Bahia, 40.170-115, Salvador, BA, Brazil; School of Medicine, University Center of Technology and Science, 41.800-700, Salvador, BA, Brazil.
| | | | - Marcelo Sobral da Silva
- Department of Pharmaceutical Sciences, Federal University of Paraíba, 58.050-585, João Pessoa, PB, Brazil.
| | - Milena Botelho Pereira Soares
- Gonçalo Moniz Institute, FIOCRUZ, 40.296-710, Salvador, BA, Brazil; Institute of Advanced Systems in Health, SENAI CIMATEC, 41.650-010, Salvador, BA, Brazil.
| | - Cristiane Flora Villarreal
- School of Pharmacy, Federal University of Bahia, 40.170-115, Salvador, BA, Brazil; Gonçalo Moniz Institute, FIOCRUZ, 40.296-710, Salvador, BA, Brazil.
| |
Collapse
|
4
|
Chibli LA, de Lima BR, Carneiro AM, Figueiró HC, Cicek SS, Spiegler V, Funari CS. Toward a More Sustainable Sample Preparation in Phytochemistry: Case Studies in Four Subclasses of Alkaloids. JOURNAL OF NATURAL PRODUCTS 2024; 87:470-479. [PMID: 38381880 DOI: 10.1021/acs.jnatprod.3c01048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/23/2024]
Abstract
The fact that alkaloids are bases has been the most explored chemical feature of their extraction and purification procedures. The main drawback of these procedures is that they employ undesirable chemicals, with HCl and CH2Cl2 probably being the most commonly employed chemicals in their subsequent steps. This work tested the hypothesis that advantages in recovery efficiency support this common practice. Experiments were conducted in three laboratories, monitoring the alkaloids harmine (1), boldine (2), vincamine (3), and mescaline (4) extracted from Banisteriopsis caapi, Peumus boldus, Vinca minor, and Trichocereus macrogonus var. pachanoi, respectively. The research demonstrated that HCl could be replaced with citric acid (CA) without loss or even better extraction performance. The recommended EtOAc could completely replace CH2Cl2 in three out of four study cases and partially in the fourth case without harming the extraction efficiency. In addition, the alternative solvents tert-amyl methyl ether (TAME) and n-butyl acetate (BuOAc) could enhance the extraction of alkaloids. These results might incentivize natural products laboratories to consider sustainability more routinely, thus being closer to current practices in the pharmaceutical industry, which has been replacing solvents and processes with greener ones.
Collapse
Affiliation(s)
- Lucas Apolinário Chibli
- Green Biotech Network, School of Agricultural Sciences, São Paulo State University (UNESP), 18610-034 Botucatu, Brazil
| | - Bruna Ribeiro de Lima
- Green Biotech Network, School of Agricultural Sciences, São Paulo State University (UNESP), 18610-034 Botucatu, Brazil
| | - Ariadne Magalhães Carneiro
- Green Biotech Network, School of Agricultural Sciences, São Paulo State University (UNESP), 18610-034 Botucatu, Brazil
| | - Harley Cardoso Figueiró
- Green Biotech Network, School of Agricultural Sciences, São Paulo State University (UNESP), 18610-034 Botucatu, Brazil
| | - Serhat Sezai Cicek
- Department of Pharmaceutical Biology, Kiel University, Gutenbergstrase 76, 24118 Kiel, Germany
- Department of Biotechnology, Hamburg University of Applied Sciences, Ulmentliet 20, 21033 Hamburg, Germany
| | - Verena Spiegler
- Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, 48149 Münster, Germany
| | - Cristiano Soleo Funari
- Green Biotech Network, School of Agricultural Sciences, São Paulo State University (UNESP), 18610-034 Botucatu, Brazil
| |
Collapse
|
5
|
Tshikhudo PP, Mabhaudhi T, Koorbanally NA, Mudau FN, Avendaño Caceres EO, Popa D, Calina D, Sharifi-Rad J. Anticancer Potential of β-Carboline Alkaloids: An Updated Mechanistic Overview. Chem Biodivers 2024; 21:e202301263. [PMID: 38108650 DOI: 10.1002/cbdv.202301263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2023] [Revised: 11/10/2023] [Accepted: 12/18/2023] [Indexed: 12/19/2023]
Abstract
his comprehensive review is designed to evaluate the anticancer properties of β-carbolines derived from medicinal plants, with the ultimate goal of assessing their suitability and potential in cancer treatment, management, and prevention. An exhaustive literature survey was conducted on a wide array of β-carbolines including, but not limited to, harmaline, harmine, harmicine, harman, harmol, harmalol, pinoline, tetrahydroharmine, tryptoline, cordysinin C, cordysinin D, norharmane, and perlolyrine. Various analytical techniques were employed to identify and screen these compounds, followed by a detailed analysis of their anticancer mechanisms. Natural β-carbolines such as harmaline and harmine have shown promising inhibitory effects on the growth of cancer cells, as evidenced by multiple in vitro and in vivo studies. Synthetically derived β-carbolines also displayed noteworthy anticancer, neuroprotective, and cognitive-enhancing effects. The current body of research emphasizes the potential of β-carbolines as a unique source of bioactive compounds for cancer treatment. The diverse range of β-carbolines derived from medicinal plants can offer valuable insights into the development of new therapeutic strategies for cancer management and prevention.
Collapse
Affiliation(s)
- Phumudzo P Tshikhudo
- Department of Agriculture, Land Reform and Rural Development, Directorate Plant Health, Division Pest Risk Analysis, Arcadia, Pretoria, South Africa
| | - Tafadzwanashe Mabhaudhi
- Centre for Transformative Agricultural and Food Systems, School of Agricultural, Earth and Environmental Sciences, University of KwaZulu-Natal, P. Bag X01, Scottsville, 3209, Pietermaritzburg, South Africa
| | - Neil A Koorbanally
- School of Chemistry and Physics, University of KwaZulu-Natal, Private Bag X54001, Durban, 4000, South Africa
| | - Fhatuwani N Mudau
- School of Agricultural, Earth and Environmental Sciences, University of KwaZulu-Natal, P. Bag X01, Scottsville, 3209, Pietermaritzburg, South Africa
| | - Edgardo Oscar Avendaño Caceres
- Departamento de quimica e ingenieria Quimica, Universidad Nacional Jorge Basadre Grohmann. Avenida Miraflores s/n, Tacna, 23001, Perú
| | - Dragos Popa
- Department of Plastic Surgery, University of Medicine and Pharmacy of Craiova, 200349, Craiova, Romania
| | - Daniela Calina
- Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349, Craiova, Romania
| | | |
Collapse
|
6
|
Ultrasensitive quantification of trace amines based on N-phosphorylation labeling chip 2D LC-QQQ/MS. J Pharm Anal 2023; 13:315-322. [PMID: 37102107 PMCID: PMC10123937 DOI: 10.1016/j.jpha.2023.02.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Revised: 01/29/2023] [Accepted: 02/09/2023] [Indexed: 02/15/2023] Open
Abstract
Trace amines (TAs) are metabolically related to catecholamine and associated with cancer and neurological disorders. Comprehensive measurement of TAs is essential for understanding pathological processes and providing proper drug intervention. However, the trace amounts and chemical instability of TAs challenge quantification. Here, diisopropyl phosphite coupled with chip two-dimensional (2D) liquid chromatography tandem triple-quadrupole mass spectrometry (LC-QQQ/MS) was developed to simultaneously determine TAs and associated metabolites. The results showed that the sensitivities of TAs increased up to 5520 times compared with those using nonderivatized LC-QQQ/MS. This sensitive method was utilized to investigate their alterations in hepatoma cells after treatment with sorafenib. The significantly altered TAs and associated metabolites suggested that phenylalanine and tyrosine metabolic pathways were related to sorafenib treatment in Hep3B cells. This sensitive method has great potential to elucidate the mechanism and diagnose diseases considering that an increasing number of physiological functions of TAs have been discovered in recent decades.
Collapse
|
7
|
Politi M, Tresca G, Menghini L, Ferrante C. Beyond the Psychoactive Effects of Ayahuasca: Cultural and Pharmacological Relevance of Its Emetic and Purging Properties. PLANTA MEDICA 2022; 88:1275-1286. [PMID: 34794194 DOI: 10.1055/a-1675-3840] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
The herbal preparation ayahuasca has been an important part of ritual and healing practices, deployed to access invisible worlds in several indigenous groups in the Amazon basin and among mestizo populations of South America. The preparation is usually known to be composed of two main plants, Banisteriopsis caapi and Psychotria viridis, which produce both hallucinogenic and potent purging and emetic effects; currently, these are considered its major pharmacological activities. In recent decades, the psychoactive and visionary effect of ayahuasca has been highly sought after by the shamanic tourism community, which led to the popularization of ayahuasca use globally and to a cultural distancing from its traditional cosmological meanings, including that of purging and emesis. Further, the field of ethnobotany and ethnopharmacology has also produced relatively limited data linking the phytochemical diversity of ayahuasca with the different degrees of its purging and emetic versus psychoactive effects. Similarly, scientific interest has also principally addressed the psychological and mental health effects of ayahuasca, overlooking the cultural and pharmacological importance of the purging and emetic activity. The aim of this review is therefore to shed light on the understudied purging and emetic effect of ayahuasca herbal preparation. It firstly focuses on reviewing the cultural relevance of emesis and purging in the context of Amazonian traditions. Secondly, on the basis of the main known phytochemicals described in the ayahuasca formula, a comprehensive pharmacological evaluation of their emetic and purging properties is presented.
Collapse
Affiliation(s)
- Matteo Politi
- Department of Pharmacy, Botanic Garden "Giardino dei Semplici", Università degli Studi "Gabriele d'Annunzio", Chieti, Italy
- Research Department, Center for Drug Addiction Treatment and Research on Traditional Medicines - Takiwasi, Tarapoto, Peru
| | - Giorgia Tresca
- Department of Pharmacy, Botanic Garden "Giardino dei Semplici", Università degli Studi "Gabriele d'Annunzio", Chieti, Italy
| | - Luigi Menghini
- Department of Pharmacy, Botanic Garden "Giardino dei Semplici", Università degli Studi "Gabriele d'Annunzio", Chieti, Italy
| | - Claudio Ferrante
- Department of Pharmacy, Botanic Garden "Giardino dei Semplici", Università degli Studi "Gabriele d'Annunzio", Chieti, Italy
| |
Collapse
|
8
|
Rodríguez L, López A, Moyna G, Seoane GA, Davyt D, Vázquez Á, Hernández G, Carrera I. New Insights into the Chemical Composition of Ayahuasca. ACS OMEGA 2022; 7:12307-12317. [PMID: 35449956 PMCID: PMC9016809 DOI: 10.1021/acsomega.2c00795] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Accepted: 03/21/2022] [Indexed: 06/14/2023]
Abstract
Ayahuasca is a psychedelic beverage originally from the Amazon rainforest used in different shamanic settings for medicinal, spiritual, and cultural purposes. It is prepared by boiling in water an admixture of the Amazonian vine Banisteriopsis caapi, which is a source of β-carboline alkaloids, with plants containing N,N-dimethyltryptamine, usually Psychotria viridis. While previous studies have focused on the detection and quantification of the alkaloids present in the drink, less attention has been given to other nonalkaloid components or the composition of the solids suspended in the beverage, which may also affect its psychoactive properties. In this study, we used nuclear magnetic resonance (NMR) and liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) to study the composition of ayahuasca samples, to determine their alkaloid qualitative and quantitative profiles, as well as other major soluble and nonsoluble components. For the first time, fructose was detected as a major component of the samples, while harmine (a β-carboline previously described as an abundant alkaloid in ayahuasca) was found to be present in the solids suspended in the beverage. In addition, N,N-dimethyltryptamine (DMT), harmine, tetrahydroharmine, harmaline, and harmol were identified as the major alkaloids present in extracts of all samples. Finally, a novel, easy, and fast method using quantitative NMR was developed and validated to simultaneously quantify the content of these alkaloids found in each ayahuasca sample.
Collapse
Affiliation(s)
- Luisina Rodríguez
- Laboratorio
de Farmacognosia, Departamento de Química Orgánica, Universidad de la República, Avenue General Flores 2124, Montevideo 11800, Uruguay
- Laboratorio
de Síntesis Orgánica, Departamento de Química
Orgánica, Universidad de la República, Avenue General Flores 2124, Montevideo 11800, Uruguay
- Arché-
Núcleo Interdisciplinario de Estudios sobre Psicodélicos-
Espacio Interdisciplinario, Universidad
de la República, José Enrique Rodó 1843, Montevideo 11200, Uruguay
| | - Andrés López
- Departamento
de Química del Litoral, Centro Universitario Regional Litoral
Norte, Universidad de la República, Ruta 3, km 363, Paysandú 60000, Uruguay
| | - Guillermo Moyna
- Departamento
de Química del Litoral, Centro Universitario Regional Litoral
Norte, Universidad de la República, Ruta 3, km 363, Paysandú 60000, Uruguay
| | - Gustavo A. Seoane
- Laboratorio
de Síntesis Orgánica, Departamento de Química
Orgánica, Universidad de la República, Avenue General Flores 2124, Montevideo 11800, Uruguay
- Arché-
Núcleo Interdisciplinario de Estudios sobre Psicodélicos-
Espacio Interdisciplinario, Universidad
de la República, José Enrique Rodó 1843, Montevideo 11200, Uruguay
| | - Danilo Davyt
- Laboratorio
de Química Farmacéutica, Departamento de Química
Orgánica, Universidad de la República, Avenue General Flores 2124, Montevideo 11800, Uruguay
| | - Álvaro Vázquez
- Laboratorio
de Farmacognosia, Departamento de Química Orgánica, Universidad de la República, Avenue General Flores 2124, Montevideo 11800, Uruguay
- Arché-
Núcleo Interdisciplinario de Estudios sobre Psicodélicos-
Espacio Interdisciplinario, Universidad
de la República, José Enrique Rodó 1843, Montevideo 11200, Uruguay
| | - Gonzalo Hernández
- Laboratorio
de Resonancia Magnética Nuclear, Departamento de Química
Orgánica, Universidad de la República, Avenue General Flores 2124, Montevideo 11800, Uruguay
| | - Ignacio Carrera
- Laboratorio
de Síntesis Orgánica, Departamento de Química
Orgánica, Universidad de la República, Avenue General Flores 2124, Montevideo 11800, Uruguay
- Arché-
Núcleo Interdisciplinario de Estudios sobre Psicodélicos-
Espacio Interdisciplinario, Universidad
de la República, José Enrique Rodó 1843, Montevideo 11200, Uruguay
| |
Collapse
|
9
|
Daldegan-Bueno D, Favaro VM, Tófoli LF, Sussulini A, Cassas F, Oliveira MGM. Ayahuasca Lyophilization (Freeze-drying) Protocol with Pre- and Post-procedure Alkaloids Quantification. J Psychoactive Drugs 2021; 54:278-283. [PMID: 34530685 DOI: 10.1080/02791072.2021.1971342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Ayahuasca is a psychoactive brew from the decoction of different Amazonian plants, traditionally used in several cultures, religions, and rituals. Scientific studies with ayahuasca are rapidly increasing due to its subjective effects and therapeutic potential. Although ayahuasca is traditionally used in its liquid presentation, lyophilized (freeze-dried) ayahuasca is often used in scientific experimentation settings. However, there is no standard process or guideline to freeze-dry ayahuasca nor comparison of the chemical profile between the liquid and freeze-dried presentations. Therefore, we describe a reproducible five-day protocol for ayahuasca lyophilization with alkaloids quantification by liquid chromatography coupled to tandem mass spectrometry of both the liquid and the final freeze-dried ayahuasca. By the end of the protocol, approximately 295 g of freeze-dried extract with similar alkaloids concentration were obtained from two liters of ayahuasca (dry matter: 14.75 %). The final extract was stored for three years inside a vacuum desiccator (approximately 6°C) with its texture quality preserved. Further studies should address the impact of different storage conditions and the lyophilization on the alkaloids' quantity of the freeze-dried ayahuasca, especially the use of heat in regards to the β-carbolines.
Collapse
Affiliation(s)
- Dimitri Daldegan-Bueno
- Schools of Population Health and Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.,Department of Psychobiology, Federal University of São Paulo (Unifesp), São Paulo, Brazil.,Interdisciplinary Cooperation for Ayahuasca Research and Outreach (Icaro), School of Medical Sciences, State University of Campinas (Unicamp), State University of Campinas, Campinas, Brazil
| | - Vanessa Manchim Favaro
- Department of Psychobiology, Federal University of São Paulo (Unifesp), São Paulo, Brazil
| | - Luís Fernando Tófoli
- Interdisciplinary Cooperation for Ayahuasca Research and Outreach (Icaro), School of Medical Sciences, State University of Campinas (Unicamp), State University of Campinas, Campinas, Brazil.,Otto Richard Gottlieb Bioorganic Chemistry Lab (Labiorg), Institute of Environmental, Chemical and Pharmaceutical Sciences (Icaqf/unifesp), Chemistry Department, Federal University of São Paulo (Unifesp), São Paulo, Brazil
| | - Alessandra Sussulini
- Laboratory of Bioanalytics and Integrated Omics (Labiomics), Institute of Chemistry, State University of Campinas (Unicamp), Campinas, Brazil
| | - Fernando Cassas
- Interdisciplinary Cooperation for Ayahuasca Research and Outreach (Icaro), School of Medical Sciences, State University of Campinas (Unicamp), State University of Campinas, Campinas, Brazil.,Otto Richard Gottlieb Bioorganic Chemistry Lab (Labiorg), Institute of Environmental, Chemical and Pharmaceutical Sciences (Icaqf/unifesp), Chemistry Department, Federal University of São Paulo (Unifesp), São Paulo, Brazil
| | - Maria Gabriela Menezes Oliveira
- Department of Psychobiology, Federal University of São Paulo (Unifesp), São Paulo, Brazil.,Interdisciplinary Cooperation for Ayahuasca Research and Outreach (Icaro), School of Medical Sciences, State University of Campinas (Unicamp), State University of Campinas, Campinas, Brazil
| |
Collapse
|
10
|
Overview of the major classes of new psychoactive substances, psychoactive effects, analytical determination and conformational analysis of selected illegal drugs. OPEN CHEM 2021. [DOI: 10.1515/chem-2021-0196] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Abstract
The misuse of psychoactive substances is attracting a great deal of attention from the general public. An increase use of psychoactive substances is observed among young people who do not have enough awareness of the harmful effects of these substances. Easy access to illicit drugs at low cost and lack of effective means of routine screening for new psychoactive substances (NPS) have contributed to the rapid increase in their use. New research and evidence suggest that drug use can cause a variety of adverse psychological and physiological effects on human health (anxiety, panic, paranoia, psychosis, and seizures). We describe different classes of these NPS drugs with emphasis on the methods used to identify them and the identification of their metabolites in biological specimens. This is the first review that thoroughly gives the literature on both natural and synthetic illegal drugs with old known data and very hot new topics and investigations, which enables the researcher to use it as a starting point in the literature exploration and planning of the own research. For the first time, the conformational analysis was done for selected illegal drugs, giving rise to the search of the biologically active conformations both theoretically and using lab experiments.
Collapse
|
11
|
Chambers M, Appley MG, Longo CM, Musah RA. Detection and Quantification of Psychoactive N, N-Dimethyltryptamine in Ayahuasca Brews by Ambient Ionization High-Resolution Mass Spectrometry. ACS OMEGA 2020; 5:28547-28554. [PMID: 33195905 PMCID: PMC7658922 DOI: 10.1021/acsomega.0c03196] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Accepted: 09/11/2020] [Indexed: 05/04/2023]
Abstract
The United Nations Office on Drugs and Crime designated twenty psychoactive botanical species as "plants of concern" because of their increased recreational abuse. Four of these are used to prepare ayahuasca brews. The complexity of the plant matrices, as well as the beverage itself, make the identification and quantification of the Schedule I component, N,N-dimethyltryptamine (DMT), a time-consuming and resource-intensive endeavor when performed using conventional approaches previously reported. Reported here is the development of a rapid validated method for the quantification of DMT in ayahuasca by direct analysis in real time-high-resolution mass spectrometry (DART-HRMS). This ambient ionization approach also enables identification of ayahuasca through detection of the secondary metabolites associated with its plant constituents. Analysis of six ayahuasca brews created using different combinations of DMT/harmala alkaloid-containing plants resulted in beverages with DMT levels of 45.7-230.5 mg/L. The detected amounts were consistent with previously reported values determined by conventional approaches.
Collapse
|
12
|
Gonçalves J, Luís Â, Gradillas A, García A, Restolho J, Fernández N, Domingues F, Gallardo E, Duarte AP. Ayahuasca Beverages: Phytochemical Analysis and Biological Properties. Antibiotics (Basel) 2020; 9:antibiotics9110731. [PMID: 33114334 PMCID: PMC7690887 DOI: 10.3390/antibiotics9110731] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2020] [Revised: 10/19/2020] [Accepted: 10/22/2020] [Indexed: 12/15/2022] Open
Abstract
Ayahuasca is a psychoactive beverage, originally consumed by indigenous Amazon tribes, of which consumption has been increasing worldwide. The aim of this study was to evaluate the phytochemical profile, as well as the antioxidant, anti-inflammatory and antimicrobial properties of decoctions of four individual plants, a commercial mixture and four mixtures of two individual plants used in the Ayahuasca preparation. For this purpose, a phytochemical characterization was performed, determining the content of flavonoids, total phenolic compounds, and analyzing the phenolic profile. Besides, 48 secondary metabolites were investigated by ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC-Q/TOF-MS) and their concentration estimated with real standards when present. The antioxidant activity was evaluated by both the β-carotene bleaching test and DPPH free radical scavenging assay, and the anti-inflammatory activity was determined by a protein denaturation method. Finally, the antimicrobial properties were evaluated using the disc diffusion assay, resazurin microtiter method, anti-quorum sensing and anti-biofilm activity assays. The obtained results showed that, in general, the samples have a high content of phenolic compounds and flavonoids with noticeable differences, reflecting on remarkable antioxidant and anti-inflammatory activities. Significant antimicrobial properties were also observed, with emphasis on the effect of B. caapi and P. harmala on planktonic and biofilm cells of A. baumannii, inhibiting both the biofilm formation and the production of violacein pigment.
Collapse
Affiliation(s)
- Joana Gonçalves
- Centro de Investigação em Ciências da Saúde (CICS-UBI), Universidade da Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal; (J.G.); (J.R.); (F.D.); (A.P.D.)
- Laboratório de Fármaco-Toxicologia, UBI Medical, Universidade da Beira Interior, Estrada Municipal 506, 6200-284 Covilhã, Portugal
| | - Ângelo Luís
- Centro de Investigação em Ciências da Saúde (CICS-UBI), Universidade da Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal; (J.G.); (J.R.); (F.D.); (A.P.D.)
- Laboratório de Fármaco-Toxicologia, UBI Medical, Universidade da Beira Interior, Estrada Municipal 506, 6200-284 Covilhã, Portugal
- Correspondence: (Â.L.); (E.G.); Tel.: +351-275-329-002/3 (Â.L.); +351-275-329-002/3 (E.G.)
| | - Ana Gradillas
- CEMBIO, Center for Metabolomics and Bioanalysis, Facultad de Farmacia, Universidad San Pablo CEU, CEU Universities, Campus Monteprincipe, Boadilla del Monte, 28668 Madrid, Spain; (A.G.); (A.G.)
| | - Antonia García
- CEMBIO, Center for Metabolomics and Bioanalysis, Facultad de Farmacia, Universidad San Pablo CEU, CEU Universities, Campus Monteprincipe, Boadilla del Monte, 28668 Madrid, Spain; (A.G.); (A.G.)
| | - José Restolho
- Centro de Investigação em Ciências da Saúde (CICS-UBI), Universidade da Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal; (J.G.); (J.R.); (F.D.); (A.P.D.)
| | - Nicolás Fernández
- Cátedra de Toxicología y Química Legal, Laboratorio de Asesoramiento Toxicológico Analítico (CENATOXA), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, C1113AAD Buenos Aires, Argentina;
| | - Fernanda Domingues
- Centro de Investigação em Ciências da Saúde (CICS-UBI), Universidade da Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal; (J.G.); (J.R.); (F.D.); (A.P.D.)
| | - Eugenia Gallardo
- Centro de Investigação em Ciências da Saúde (CICS-UBI), Universidade da Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal; (J.G.); (J.R.); (F.D.); (A.P.D.)
- Laboratório de Fármaco-Toxicologia, UBI Medical, Universidade da Beira Interior, Estrada Municipal 506, 6200-284 Covilhã, Portugal
- Correspondence: (Â.L.); (E.G.); Tel.: +351-275-329-002/3 (Â.L.); +351-275-329-002/3 (E.G.)
| | - Ana Paula Duarte
- Centro de Investigação em Ciências da Saúde (CICS-UBI), Universidade da Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal; (J.G.); (J.R.); (F.D.); (A.P.D.)
- Laboratório de Fármaco-Toxicologia, UBI Medical, Universidade da Beira Interior, Estrada Municipal 506, 6200-284 Covilhã, Portugal
| |
Collapse
|
13
|
Giovannetti C, Garcia Arce S, Rush B, Mendive F. Pilot Evaluation of a Residential Drug Addiction Treatment Combining Traditional Amazonian Medicine, Ayahuasca and Psychotherapy on Depression and Anxiety. J Psychoactive Drugs 2020; 52:472-481. [DOI: 10.1080/02791072.2020.1789247] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Cecile Giovannetti
- Institute for Tropical Medicine and International Health, Charité Universitätmedizin Berlin, Berlin, Germany
| | - Sara Garcia Arce
- Takiwasi Center for Rehabilitation of Drug Addicts and Research on Traditional Medicine, Tarapoto, Peru
| | - Brian Rush
- Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada
- Departments of Psychiatry and Public Health Sciences, University of Toronto, Toronto, Canada
| | - Fernando Mendive
- Takiwasi Center for Rehabilitation of Drug Addicts and Research on Traditional Medicine, Tarapoto, Peru
| |
Collapse
|
14
|
Biodiversity of β-Carboline Profile of Banisteriopsis caapi and Ayahuasca, a Plant and a Brew with Neuropharmacological Potential. PLANTS 2020; 9:plants9070870. [PMID: 32660098 PMCID: PMC7411993 DOI: 10.3390/plants9070870] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Revised: 06/19/2020] [Accepted: 06/20/2020] [Indexed: 11/17/2022]
Abstract
Ayahuasca is a psychoactive infusion with a large pharmacological application normally prepared with Banisteriopsis caapi, which contains the monoamine oxidase inhibitors β-carbolines, and Psichotria virids, which contains the serotonin receptor agonist N,N dimethyltryptamine (DMT). The objectives of this study were to investigate the chemical profile of B. caapi and of ayahuasca collected in various Brazilian regions. In total, 176 plant lianas, of which 159 B.caapi and 33 ayahuasca samples were analyzed. Dried liana samples were powdered, extracted with methanol, diluted, and analyzed by LC-MS/MS. Ayahuasca samples were diluted and analyzed. Mean concentrations in B. caapi were 4.79 mg/g harmine, 0.451 mg/g harmaline, and 2.18 mg/g tetrahydroharmine (THH), with a high variability among the samples (RSD from 78.9 to 170%). Native B. caapi samples showed significantly higher harmine concentrations than cultivated ones, and samples from the Federal District/Goiás had higher THH content than those collected in the State of Acre. The other Malpighiaceae samples did not contain β-carbolines, except for one D. pubipetala sample. Concentrations in ayahuasca samples ranged from 0.109 to 7.11 mg/mL harmine, 0.012 to 0.945 mg/mL harmaline, 0.09 to 3.05 mg/mL THH, and 0.10 to 3.12 mg/mL DMT. The analysis of paired ayahuasca/B. caapi confirmed that harmine is reduced to harmaline and to THH during the brew preparation. This is the largest study conducted with Malpighiaceae samples and showed a large variability in the main β-carbolines present in B. caapi. This biodiversity is a challenge for standardization of the material used in ethnopharmacological studies of B.caapi and ayahuasca.
Collapse
|
15
|
Katchborian-Neto A, Santos WT, Nicácio KJ, Corrêa JOA, Murgu M, Martins TMM, Gomes DA, Goes AM, Soares MG, Dias DF, Chagas-Paula DA, Paula ACC. Neuroprotective potential of Ayahuasca and untargeted metabolomics analyses: applicability to Parkinson's disease. JOURNAL OF ETHNOPHARMACOLOGY 2020; 255:112743. [PMID: 32171895 DOI: 10.1016/j.jep.2020.112743] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/31/2019] [Revised: 02/18/2020] [Accepted: 03/04/2020] [Indexed: 06/10/2023]
Abstract
ETHNOPHARMACOLOGY RELEVANCE Ayahuasca is a tea produced through decoction of Amazonian plants. It has been used for centuries by indigenous people of South America. The beverage is considered to be an ethnomedicine, and it is traditionally used for the treatment of a wide range of diseases, including neurological illness. Besides, some scientific evidence suggests it may be applicable to Parkinson's disease (PD) treatment. Thus, Ayahuasca deserves in depth studies to clarify its potential role in this disease. AIM OF THE STUDY This study aimed to use an untargeted metabolomics approach to evaluate the neuroprotective potential of the Ayahuasca beverage, the extracts from its matrix plants (Banisteriopsis caapi and Psychotria viridis), its fractions and its main alkaloids on the viability of SH-SY5Y neuroblastoma cells in an in vitro PD model. MATERIAL AND METHODS The cytotoxicity of Ayahuasca, crude extracts, and fractions of B. caapi and P. viridis, as well as neuroprotection promoted by these samples in a 6-hydroxydopamine (6-OHDA)-induced neurodegeneration model, were evaluated by the MTT assay at two time-points: 48 h (T1) and 72 h (T2). The main alkaloids from Ayahuasca matrix plants, harmine (HRE) and N,N-dimethyltryptamine (DMT), were also isolated and evaluated. An untargeted metabolomics approach was developed to explore the chemical composition of samples with neuroprotective activity. Ultra-Performance Liquid Chromatography coupled to Electrospray Ionisation and Time-of-Flight (UPLC-ESI-TOF) metabolome data was treated and further analysed using multivariate statistical analyses (MSA): principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA). The metabolites were dereplicated using the Dictionary of Natural Products and an in house database. The main alkaloids were also quantified by UPLC-MS/MS. RESULTS The samples did not cause cytotoxicity in vitro and three of samples intensely increased cell viability at T1. The crude extracts, alkaloid fractions and HRE demonstrated remarkable neuroprotective effect at T2 while the hydroalcoholic fractions demonstrated this neuroprotective effect at T1 and T2. Several compounds from different classes, such as β-carbolines and monoterpene indole alkaloids (MIAs) were revealed correlated with this property by MSA. Additionally, a total of 2419 compounds were detected in both ionisation modes. HRE showed potent neuroprotective action at 72 h, but it was not among the metabolites positively correlated with the most efficacious neuroprotective profile at either time (T1 and T2). Furthermore, DMT was statistically important to differentiate the dataset (VIP value > 1), although it did not exhibit sufficient neuroprotective activity by in vitro assay, neither a positive correlation with T1 and T2 neuroprotective profile, which corroborated the MSA results. CONCLUSION The lower doses of the active samples stimulated neuronal cell proliferation and/or displayed the most efficacious neuroprotection profile, namely by preventing neuronal damage and improving cell viability against 6-OHDA-induced toxicity. Intriguingly, the hydroalcoholic fractions exhibited enhanced neuroprotective effects when compared to other samples and isolated alkaloids. This finding corroborates the significance of a holistic approach. The results demonstrate that Ayahuasca and its base plants have potential applicability for PD treatment and to prevent its progression differently from current drugs to treat PD.
Collapse
Affiliation(s)
- Albert Katchborian-Neto
- Chemistry Institute, Federal University of Alfenas, 37130-001, Alfenas, Minas Gerais, Brazil
| | - Wanderleya T Santos
- School of Pharmacy, Federal University of Juiz de Fora, 36036-900, Juiz de Fora, Minas Gerais, Brazil
| | - Karen J Nicácio
- Chemistry Institute, Federal University of Alfenas, 37130-001, Alfenas, Minas Gerais, Brazil
| | - José O A Corrêa
- School of Pharmacy, Federal University of Juiz de Fora, 36036-900, Juiz de Fora, Minas Gerais, Brazil
| | - Michael Murgu
- Waters Corporation, Alameda Tocantins 125, 27th Floor, Alphaville, 06455-020, São Paulo, São Paulo, Brazil
| | - Thaís M M Martins
- Biological Sciences Institute, Federal University of Minas Gerais, 31270-901, Belo Horizonte, Minas Gerais, Brazil
| | - Dawidson A Gomes
- Biological Sciences Institute, Federal University of Minas Gerais, 31270-901, Belo Horizonte, Minas Gerais, Brazil
| | - Alfredo M Goes
- Biological Sciences Institute, Federal University of Minas Gerais, 31270-901, Belo Horizonte, Minas Gerais, Brazil
| | - Marisi G Soares
- Chemistry Institute, Federal University of Alfenas, 37130-001, Alfenas, Minas Gerais, Brazil
| | - Danielle F Dias
- Chemistry Institute, Federal University of Alfenas, 37130-001, Alfenas, Minas Gerais, Brazil
| | - Daniela A Chagas-Paula
- Chemistry Institute, Federal University of Alfenas, 37130-001, Alfenas, Minas Gerais, Brazil.
| | - Ana C C Paula
- School of Pharmacy, Federal University of Juiz de Fora, 36036-900, Juiz de Fora, Minas Gerais, Brazil.
| |
Collapse
|
16
|
de Oliveira Silveira G, Guimarães dos Santos R, Rebello Lourenço F, Novak Rossi G, Hallak JEC, Yonamine M. Stability Evaluation of DMT and Harmala Alkaloids in Ayahuasca Tea Samples. Molecules 2020; 25:molecules25092072. [PMID: 32365548 PMCID: PMC7248686 DOI: 10.3390/molecules25092072] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2020] [Revised: 04/22/2020] [Accepted: 04/24/2020] [Indexed: 11/16/2022] Open
Abstract
Ayahuasca tea is a hallucinogenic beverage used for religious purposes in Brazil and many other countries that has therapeutic potential in the treatment of some mental health disorders. In the context of psychedelic research, quantification of the tea's main alkaloids prior to its administration in animal or human studies is essential. For this reason, this study aims to provide information regarding the stability of the main ayahuasca alkaloids (dimethyltryptamine, DMT; harmine, HRM; tetrahydroharmine, THH; harmaline, HRL) in three different conditions: (1) A year stored in a refrigerator either in plastic or glass containers, (2) seven days at 37 °C to reproduce usual mail transportation, and (3) after three freeze-thaw cycles. Samples were quantified after a dilute-and-shoot procedure using liquid chromatography tandem mass spectrometry (LC-ESI-MS/MS). There was no significant degradation of DMT concentration over time in all tested conditions. Harmala alkaloids (THH, HRL, and HRM) showed important variations after long-term and high-temperature storages. Although DMT has proven to be stable in all studied conditions, the harmala alkaloids revealed intense degradation and even concentration increment. This may be caused by degradation, alkaloid inter-conversion, and leaching from tea precipitate material. Therefore, ayahuasca quantification before administration in controlled sets is mandatory.
Collapse
Affiliation(s)
- Gabriela de Oliveira Silveira
- Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo 05508-000, Brazil;
- Correspondence:
| | - Rafael Guimarães dos Santos
- Department of Neurosciences and Behaviour, University of São Paulo, Ribeirão Preto 14049-900, Brazil; (R.G.d.S.); (G.N.R.); (J.E.C.H.)
- National Institute of Science and Technology—Translational Medicine, Ribeirão Preto 14049-900, Brazil
| | - Felipe Rebello Lourenço
- Department of Pharmacy, School of Pharmaceutical Sciences, University of São Paulo, São Paulo 05508-000, Brazil;
| | - Giordano Novak Rossi
- Department of Neurosciences and Behaviour, University of São Paulo, Ribeirão Preto 14049-900, Brazil; (R.G.d.S.); (G.N.R.); (J.E.C.H.)
| | - Jaime E. C. Hallak
- Department of Neurosciences and Behaviour, University of São Paulo, Ribeirão Preto 14049-900, Brazil; (R.G.d.S.); (G.N.R.); (J.E.C.H.)
- National Institute of Science and Technology—Translational Medicine, Ribeirão Preto 14049-900, Brazil
| | - Mauricio Yonamine
- Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo 05508-000, Brazil;
| |
Collapse
|
17
|
Lo Faro AF, Di Trana A, La Maida N, Tagliabracci A, Giorgetti R, Busardò FP. Biomedical analysis of New Psychoactive Substances (NPS) of natural origin. J Pharm Biomed Anal 2019; 179:112945. [PMID: 31704129 DOI: 10.1016/j.jpba.2019.112945] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2019] [Revised: 10/16/2019] [Accepted: 10/18/2019] [Indexed: 12/16/2022]
Abstract
New psychoactive substances (NPS) can be divided into two main groups: synthetic molecules and active principles of natural origin. With respect to this latter group, a wide range of alkaloids contained in plants, mainly from Asia and South America, can be included in the class of NPS of natural origin. The majority NPS of natural origin presents stimulant and/or hallucinogenic effects (e.g. Catha edulis and Ayahuasca, respectively) while few of them show sedative and relaxing properties (e.g. kratom). Few information is available in relation to the analytical identification of psychoactive principles contained in the plant material. Moreover, to our knowledge, scarce data are present in literature, about the characterization and quantification of the parent drug in biological matrices from intoxication and fatality cases. In addition, the metabolism of natural active principles has not been yet fully investigated for most of the psychoactive substances from plant material. Consequently, their identification is not frequently performed and produced metabolites are often unknown. To fill this gap, we reviewed the currently available analytical methodologies for the identification and quantification of NPS of natural origin in plant material and, whenever possible, in conventional and non-conventional biological matrices of intoxicated and dead subjects. The psychoactive principles contained in the following plants were investigated: Areca catechu, Argyreia nervosa, Ayahuasca, Catha edulis, Ipomoea violacea, Mandragora officinarum, Mitragyna speciosa, Pausinystalia yohimbe, Piper methisticum, Psilocybe, Rivea corymbosa, Salvia divinorum, Sceletium tortuosum, Lactuca virosa. From the results obtained, it can be evidenced that although several analytical methods for the simultaneous quantification of different molecules from the same plants have been developed and validated, a comprehensive method to detect active compounds from different natural specimens both in biological and non-biological matrices is still lacking.
Collapse
Affiliation(s)
- Alfredo Fabrizio Lo Faro
- Department of Excellence of Biomedical Sciences and Public Health, University "Politecnica delle Marche" of Ancona, Via Tronto 71, Ancona, Italy
| | - Annagiulia Di Trana
- Department of Excellence of Biomedical Sciences and Public Health, University "Politecnica delle Marche" of Ancona, Via Tronto 71, Ancona, Italy
| | - Nunzia La Maida
- Department of Excellence of Biomedical Sciences and Public Health, University "Politecnica delle Marche" of Ancona, Via Tronto 71, Ancona, Italy
| | - Adriano Tagliabracci
- Department of Excellence of Biomedical Sciences and Public Health, University "Politecnica delle Marche" of Ancona, Via Tronto 71, Ancona, Italy
| | - Raffaele Giorgetti
- Department of Excellence of Biomedical Sciences and Public Health, University "Politecnica delle Marche" of Ancona, Via Tronto 71, Ancona, Italy
| | - Francesco Paolo Busardò
- Department of Excellence of Biomedical Sciences and Public Health, University "Politecnica delle Marche" of Ancona, Via Tronto 71, Ancona, Italy.
| |
Collapse
|
18
|
Toxicological Aspects and Determination of the Main Components of Ayahuasca: A Critical Review. MEDICINES 2019; 6:medicines6040106. [PMID: 31635364 PMCID: PMC6963515 DOI: 10.3390/medicines6040106] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/01/2019] [Revised: 10/12/2019] [Accepted: 10/16/2019] [Indexed: 01/11/2023]
Abstract
Ayahuasca is a psychoactive beverage prepared traditionally from a mixture of the leaves and stems of Psychotria viridis and Banisteriopsis caapi, respectively, being originally consumed by indigenous Amazonian tribes for ritual and medicinal purposes. Over the years, its use has spread to other populations as a means to personal growth and spiritual connection. Also, the recreational use of its isolated compounds has become prominent. The main compounds of this tea-like preparation are N,N-dimethyltryptamine (DMT), β-Carbolines, and harmala alkaloids, such as harmine, tetrahydroharmine, and harmaline. The latter are monoamine-oxidase inhibitors and are responsible for DMT psychoactive and hallucinogenic effects on the central nervous system. Although consumers defend its use, its metabolic effects and those on the central nervous system are not fully understood yet. The majority of studies regarding the effects of this beverage and of its individual compounds are based on in vivo experiments, clinical trials, and even surveys. This paper will not only address the toxicological aspects of the ayahuasca compounds but also perform a comprehensive and critical review on the analytical methods available for their determination in biological and non-biological specimens, with special focus on instrumental developments and sample preparation approaches.
Collapse
|
19
|
Estrella-Parra EA, Almanza-Pérez JC, Alarcón-Aguilar FJ. Ayahuasca: Uses, Phytochemical and Biological Activities. NATURAL PRODUCTS AND BIOPROSPECTING 2019; 9:251-265. [PMID: 31134518 PMCID: PMC6646606 DOI: 10.1007/s13659-019-0210-5] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Accepted: 05/12/2019] [Indexed: 05/14/2023]
Abstract
Ayahuasca (caapi, yajé), is a psychoactive brew from the Amazon Basin region of South America traditionally considered a "master plant." It is prepared as a decoction from Banisteriopsis caapi and Psychotria viridis, which it is thought that it stimulates creative thinking and visual creativity. Native healers of the Orinoco and Amazon basins have used traditionally ayahuasca as a healing tool for multiple purposes, particularly to treat psychological disorders in the patients, with some beneficial effects experimentally and clinically validated. Recently, several syncretic religions, as the "União de Vegetal" (UDV) group in Brazil, have been spread around the world. The use of ayahuasca has been popularized by internet and smart-shops, bringing the psychoactive substance to new highs, emerging new "ayahuasqueros." Ayahuasca has alkaloids as β-carbolines and dimethyltryptamines, which inhibit the monoamine oxidase and active the 5-HT2A (5-hydroxytryptamine) receptor, respectively, resulting in hallucinations in the users. Ayahuasca induces a psychedelic change in the anteroposterior coupling of the electrophysiological brain oscillations in humans. Traditional ayahuasca beverage is generating pharmacological, commercial and spiritual interest among the scientific community, government people, and different populations worldwide. The goal of this article is to report about the uses, chemistry and biological activities of ayahuasca.
Collapse
Affiliation(s)
- Edgar Antonio Estrella-Parra
- Laboratorio de Farmacología. Dpto. Ciencias de la Salud. Div. C.B.S. Universidad Autónoma Metropolitana, Unidad Iztapalapa. Av. San Rafael Atlixco No. 186, Col. Vicentina, 09340, Mexico CDMX, Mexico
- Laboratorio de Fitoquímica, Laboratorio de Farmacognosia, Laboratorio de Fisiología Vegetal, Unidad UBIPRO, FES-Iztacala, UNAM, Tlalnepantla de Baz, 54090, Mexico CDMX, Mexico
| | - Julio Cesar Almanza-Pérez
- Laboratorio de Farmacología. Dpto. Ciencias de la Salud. Div. C.B.S. Universidad Autónoma Metropolitana, Unidad Iztapalapa. Av. San Rafael Atlixco No. 186, Col. Vicentina, 09340, Mexico CDMX, Mexico
| | - Francisco Javier Alarcón-Aguilar
- Laboratorio de Farmacología. Dpto. Ciencias de la Salud. Div. C.B.S. Universidad Autónoma Metropolitana, Unidad Iztapalapa. Av. San Rafael Atlixco No. 186, Col. Vicentina, 09340, Mexico CDMX, Mexico.
| |
Collapse
|
20
|
Zhang J, Bai Y, Li B, Zhou X, Si H, Zhang J. Determination and pharmacokinetics study of oxyclozanide suspension in cattle by LC-MS/MS. BMC Vet Res 2019; 15:210. [PMID: 31234851 PMCID: PMC6591842 DOI: 10.1186/s12917-019-1963-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2018] [Accepted: 06/16/2019] [Indexed: 11/19/2022] Open
Abstract
Background Oxyclozanide is an anthelmintic drug that is widely used to treat fasciolosis. However, the pharmacokinetics of oxyclozanide in cattle are not yet clearly understood. The present study was designed to develop a sensitive method to determine oxyclozanide levels in cattle plasma using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) and to study its pharmacokinetics for application in cattle. Results A simple and rapid HPLC-MS/MS analytical method was established and validated to quantify oxyclozanide levels in cattle plasma using niclosamide as the internal standard (IS) in negative ion mode. Chromatographic separation of the analytes was achieved using a C18 analytical column (75 × 4.6 mm, 2.7 μm) at 30 °C. The mobile phase comprised 0.01% v/v acetic acid (HOAc) diluted in water:acetonitrile (MeCN) (90:10% v/v) and 5 mM ammonium formate in methanol (MeOH):MeCN (75:25, v/v) at a 10:90 ratio (v/v) and was delivered at a flow rate of 0.4 mL min− 1. A good linear response across the concentration range of 0.02048–25.600 μg/mL was achieved (r2 = 0.994). The method was validated with respect to linearity, matrix effect, accuracy, precision, recovery and stability. The lower limit of quantification (LLOQ) was 0.020 μg/mL, and the extraction recovery was > 98% for oxyclozanide. The inter- and intra-day accuracy and precision of the method showed the relative standard deviation (RSD) less than 10%. The method was successfully applied to an assessment of the pharmacokinetics of oxyclozanide in cattle plasma. In healthy cattle, a single oral dose of an oxyclozanide suspension followed the one-compartment model, with a half-life (T1/2) of 64.40 ± 30.18 h, a plasma clearance rate (CL/F) of 11.426 ± 2.442 mL/h/kg, and an average area under the curve (AUC) of 965.608 ± 220.097 h*μg/mL. The peak concentration (Cmax) was 15.870 ± 2.855 μg/mL, which occurred at a peak time (Tmax) = 22.032 ± 3.343 h. Conclusions A reliable, accurate HPLC-MS/MS analytical method was established in our study and successful applied to study the pharmacokinetics of oxyclozanide in cattle plasma. These results will be useful for further evaluations of the pharmacokinetic properties of oxyclozanide or for monitoring therapeutic drugs in animals.
Collapse
Affiliation(s)
- Jili Zhang
- Key Laboratory of Veterinary Pharmaceutical Development, Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Ministry of Agriculture, Lanzhou, Gansu Province, 730050, People's Republic of China.,Key Laboratory of New Animal Drug Project of Gansu Province, Lanzhou, Gansu Province, People's Republic of China.,Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu Province, People's Republic of China
| | - Yubin Bai
- Key Laboratory of Veterinary Pharmaceutical Development, Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Ministry of Agriculture, Lanzhou, Gansu Province, 730050, People's Republic of China.,Key Laboratory of New Animal Drug Project of Gansu Province, Lanzhou, Gansu Province, People's Republic of China.,Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu Province, People's Republic of China
| | - Bing Li
- Key Laboratory of Veterinary Pharmaceutical Development, Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Ministry of Agriculture, Lanzhou, Gansu Province, 730050, People's Republic of China.,Key Laboratory of New Animal Drug Project of Gansu Province, Lanzhou, Gansu Province, People's Republic of China.,Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu Province, People's Republic of China
| | - Xuzheng Zhou
- Key Laboratory of Veterinary Pharmaceutical Development, Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Ministry of Agriculture, Lanzhou, Gansu Province, 730050, People's Republic of China.,Key Laboratory of New Animal Drug Project of Gansu Province, Lanzhou, Gansu Province, People's Republic of China.,Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu Province, People's Republic of China
| | - Hongfei Si
- Key Laboratory of Veterinary Pharmaceutical Development, Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Ministry of Agriculture, Lanzhou, Gansu Province, 730050, People's Republic of China.,Key Laboratory of New Animal Drug Project of Gansu Province, Lanzhou, Gansu Province, People's Republic of China.,Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu Province, People's Republic of China
| | - Jiyu Zhang
- Key Laboratory of Veterinary Pharmaceutical Development, Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Ministry of Agriculture, Lanzhou, Gansu Province, 730050, People's Republic of China. .,Key Laboratory of New Animal Drug Project of Gansu Province, Lanzhou, Gansu Province, People's Republic of China. .,Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu Province, People's Republic of China.
| |
Collapse
|
21
|
Hamill J, Hallak J, Dursun SM, Baker G. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness. Curr Neuropharmacol 2019; 17:108-128. [PMID: 29366418 PMCID: PMC6343205 DOI: 10.2174/1570159x16666180125095902] [Citation(s) in RCA: 67] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2017] [Revised: 11/07/2017] [Accepted: 01/24/2018] [Indexed: 01/07/2023] Open
Abstract
Background: Ayahuasca, a traditional Amazonian decoction with psychoactive properties, is made from bark of the Banisteriopsis caapi vine (containing beta-carboline alkaloids) and leaves of the Psychotria viridis bush (supplying the hallucinogen N,N-dimethyltryptamine, DMT). Originally used by indigenous shamans for the purposes of spirit communi-cation, magical experiences, healing, and religious rituals across several South American countries, ayahuasca has been in-corporated into folk medicine and spiritual healing, and several Brazilian churches use it routinely to foster a spiritual experi-ence. More recently, it is being used in Europe and North America, not only for religious or healing reasons, but also for rec-reation. Objective: To review ayahuasca’s behavioral effects, possible adverse effects, proposed mechanisms of action and potential clinical uses in mental illness. Method: We searched Medline, in English, using the terms ayahuasca, dimethyltryptamine, Banisteriopsis caapi, and Psy-chotria viridis and reviewed the relevant publications. Results: The following aspects of ayahuasca are summarized: Political and legal factors; acute and chronic psychological ef-fects; electrophysiological studies and imaging; physiological effects; safety and adverse effects; pharmacology; potential psychiatric uses. Conclusion: Many years of shamanic wisdom have indicated potential therapeutic uses for ayahuasca, and several present day studies suggest that it may be useful for treating various psychiatric disorders and addictions. The side effect profile ap-pears to be relatively mild, but more detailed studies need to be done. Several prominent researchers believe that government regulations with regard to ayahuasca should be relaxed so that it could be provided more readily to recognized, credible re-searchers to conduct comprehensive clinical trials.
Collapse
Affiliation(s)
- Jonathan Hamill
- Department of Psychiatry (Neurochemical Research Unit) and Neuroscience & Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada
| | - Jaime Hallak
- Department of Psychiatry (Neurochemical Research Unit) and Neuroscience & Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada.,Department of Neurosciences and Behavior and National Institute of Science and Technology (Translational Medicine), Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
| | - Serdar M Dursun
- Department of Psychiatry (Neurochemical Research Unit) and Neuroscience & Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada
| | - Glen Baker
- Department of Psychiatry (Neurochemical Research Unit) and Neuroscience & Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada
| |
Collapse
|
22
|
Pires JM, Mendes FR, Pires APS, Yonamine M, Amaral JLGD, Carlini EA. Pre-clinical interaction of ayahuasca, a brew used in spiritual movements, with morphine and propofol. BRAZ J PHARM SCI 2018. [DOI: 10.1590/s2175-97902018000117174] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
23
|
da Motta LG, de Morais JA, Tavares ACA, Vianna LMS, Mortari MR, Amorim RFB, Carvalho RR, Paumgartten FJR, Pic-Taylor A, Caldas ED. Maternal and developmental toxicity of the hallucinogenic plant-based beverage ayahuasca in rats. Reprod Toxicol 2018. [DOI: 10.1016/j.reprotox.2018.03.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
24
|
Sampedro F, de la Fuente Revenga M, Valle M, Roberto N, Domínguez-Clavé E, Elices M, Luna LE, Crippa JAS, Hallak JEC, de Araujo DB, Friedlander P, Barker SA, Álvarez E, Soler J, Pascual JC, Feilding A, Riba J. Assessing the Psychedelic "After-Glow" in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities. Int J Neuropsychopharmacol 2017; 20:698-711. [PMID: 28525587 PMCID: PMC5581489 DOI: 10.1093/ijnp/pyx036] [Citation(s) in RCA: 100] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2016] [Accepted: 05/17/2017] [Indexed: 12/12/2022] Open
Abstract
Background Ayahuasca is a plant tea containing the psychedelic 5-HT2A agonist N,N-dimethyltryptamine and harmala monoamine-oxidase inhibitors. Acute administration leads to neurophysiological modifications in brain regions of the default mode network, purportedly through a glutamatergic mechanism. Post-acutely, ayahuasca potentiates mindfulness capacities in volunteers and induces rapid and sustained antidepressant effects in treatment-resistant patients. However, the mechanisms underlying these fast and maintained effects are poorly understood. Here, we investigated in an open-label uncontrolled study in 16 healthy volunteers ayahuasca-induced post-acute neurometabolic and connectivity modifications and their association with mindfulness measures. Methods Using 1H-magnetic resonance spectroscopy and functional connectivity, we compared baseline and post-acute neurometabolites and seed-to-voxel connectivity in the posterior and anterior cingulate cortex after a single ayahuasca dose. Results Magnetic resonance spectroscopy showed post-acute reductions in glutamate+glutamine, creatine, and N-acetylaspartate+N-acetylaspartylglutamate in the posterior cingulate cortex. Connectivity was increased between the posterior cingulate cortex and the anterior cingulate cortex, and between the anterior cingulate cortex and limbic structures in the right medial temporal lobe. Glutamate+glutamine reductions correlated with increases in the "nonjudging" subscale of the Five Facets Mindfulness Questionnaire. Increased anterior cingulate cortex-medial temporal lobe connectivity correlated with increased scores on the self-compassion questionnaire. Post-acute neural changes predicted sustained elevations in nonjudging 2 months later. Conclusions These results support the involvement of glutamate neurotransmission in the effects of psychedelics in humans. They further suggest that neurometabolic changes in the posterior cingulate cortex, a key region within the default mode network, and increased connectivity between the anterior cingulate cortex and medial temporal lobe structures involved in emotion and memory potentially underlie the post-acute psychological effects of ayahuasca.
Collapse
Affiliation(s)
- Frederic Sampedro
- School of Medicine, Autonomous University of Barcelona, Barcelona, Spain (Mr Sampedro); Human Neuropsychopharmacology Research Group, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr de la Fuente Revenga, Ms Roberto, and Dr Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr Valle); Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Drs Valle and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Elices, Álvarez, Soler, Pascual, and Riba); Department of Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain (Dr Valle); Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, Soler, and Pascual); Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, and Pascual); Research Center for the Study of Psychointegrator Plants, Visionary Art and Consciousness, Florianópolis, Santa Catarina, Brazil (Dr Luna); Department of Neuroscience and Behavior, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil and National Institute for Translational Medicine, Ribeirão Preto, Brazil (Drs Crippa and Hallak); Brain Institute/Hospital Universitario Onofre Lopes, Natal, Brazil (Dr de Araujo); The Beckley Foundation, Beckley Park, Oxford, United Kingdom (Mr Friedlander and Mrs Feilding); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, Louisiana (Dr Barker); Department of Clinical and Health Psychology, School of Psychology, Autonomous University of Barcelona, Barcelona, Spain (Dr Soler)
| | - Mario de la Fuente Revenga
- School of Medicine, Autonomous University of Barcelona, Barcelona, Spain (Mr Sampedro); Human Neuropsychopharmacology Research Group, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr de la Fuente Revenga, Ms Roberto, and Dr Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr Valle); Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Drs Valle and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Elices, Álvarez, Soler, Pascual, and Riba); Department of Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain (Dr Valle); Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, Soler, and Pascual); Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, and Pascual); Research Center for the Study of Psychointegrator Plants, Visionary Art and Consciousness, Florianópolis, Santa Catarina, Brazil (Dr Luna); Department of Neuroscience and Behavior, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil and National Institute for Translational Medicine, Ribeirão Preto, Brazil (Drs Crippa and Hallak); Brain Institute/Hospital Universitario Onofre Lopes, Natal, Brazil (Dr de Araujo); The Beckley Foundation, Beckley Park, Oxford, United Kingdom (Mr Friedlander and Mrs Feilding); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, Louisiana (Dr Barker); Department of Clinical and Health Psychology, School of Psychology, Autonomous University of Barcelona, Barcelona, Spain (Dr Soler)
| | - Marta Valle
- School of Medicine, Autonomous University of Barcelona, Barcelona, Spain (Mr Sampedro); Human Neuropsychopharmacology Research Group, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr de la Fuente Revenga, Ms Roberto, and Dr Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr Valle); Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Drs Valle and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Elices, Álvarez, Soler, Pascual, and Riba); Department of Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain (Dr Valle); Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, Soler, and Pascual); Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, and Pascual); Research Center for the Study of Psychointegrator Plants, Visionary Art and Consciousness, Florianópolis, Santa Catarina, Brazil (Dr Luna); Department of Neuroscience and Behavior, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil and National Institute for Translational Medicine, Ribeirão Preto, Brazil (Drs Crippa and Hallak); Brain Institute/Hospital Universitario Onofre Lopes, Natal, Brazil (Dr de Araujo); The Beckley Foundation, Beckley Park, Oxford, United Kingdom (Mr Friedlander and Mrs Feilding); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, Louisiana (Dr Barker); Department of Clinical and Health Psychology, School of Psychology, Autonomous University of Barcelona, Barcelona, Spain (Dr Soler)
| | - Natalia Roberto
- School of Medicine, Autonomous University of Barcelona, Barcelona, Spain (Mr Sampedro); Human Neuropsychopharmacology Research Group, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr de la Fuente Revenga, Ms Roberto, and Dr Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr Valle); Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Drs Valle and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Elices, Álvarez, Soler, Pascual, and Riba); Department of Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain (Dr Valle); Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, Soler, and Pascual); Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, and Pascual); Research Center for the Study of Psychointegrator Plants, Visionary Art and Consciousness, Florianópolis, Santa Catarina, Brazil (Dr Luna); Department of Neuroscience and Behavior, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil and National Institute for Translational Medicine, Ribeirão Preto, Brazil (Drs Crippa and Hallak); Brain Institute/Hospital Universitario Onofre Lopes, Natal, Brazil (Dr de Araujo); The Beckley Foundation, Beckley Park, Oxford, United Kingdom (Mr Friedlander and Mrs Feilding); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, Louisiana (Dr Barker); Department of Clinical and Health Psychology, School of Psychology, Autonomous University of Barcelona, Barcelona, Spain (Dr Soler)
| | - Elisabet Domínguez-Clavé
- School of Medicine, Autonomous University of Barcelona, Barcelona, Spain (Mr Sampedro); Human Neuropsychopharmacology Research Group, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr de la Fuente Revenga, Ms Roberto, and Dr Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr Valle); Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Drs Valle and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Elices, Álvarez, Soler, Pascual, and Riba); Department of Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain (Dr Valle); Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, Soler, and Pascual); Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, and Pascual); Research Center for the Study of Psychointegrator Plants, Visionary Art and Consciousness, Florianópolis, Santa Catarina, Brazil (Dr Luna); Department of Neuroscience and Behavior, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil and National Institute for Translational Medicine, Ribeirão Preto, Brazil (Drs Crippa and Hallak); Brain Institute/Hospital Universitario Onofre Lopes, Natal, Brazil (Dr de Araujo); The Beckley Foundation, Beckley Park, Oxford, United Kingdom (Mr Friedlander and Mrs Feilding); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, Louisiana (Dr Barker); Department of Clinical and Health Psychology, School of Psychology, Autonomous University of Barcelona, Barcelona, Spain (Dr Soler)
| | - Matilde Elices
- School of Medicine, Autonomous University of Barcelona, Barcelona, Spain (Mr Sampedro); Human Neuropsychopharmacology Research Group, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr de la Fuente Revenga, Ms Roberto, and Dr Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr Valle); Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Drs Valle and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Elices, Álvarez, Soler, Pascual, and Riba); Department of Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain (Dr Valle); Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, Soler, and Pascual); Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, and Pascual); Research Center for the Study of Psychointegrator Plants, Visionary Art and Consciousness, Florianópolis, Santa Catarina, Brazil (Dr Luna); Department of Neuroscience and Behavior, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil and National Institute for Translational Medicine, Ribeirão Preto, Brazil (Drs Crippa and Hallak); Brain Institute/Hospital Universitario Onofre Lopes, Natal, Brazil (Dr de Araujo); The Beckley Foundation, Beckley Park, Oxford, United Kingdom (Mr Friedlander and Mrs Feilding); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, Louisiana (Dr Barker); Department of Clinical and Health Psychology, School of Psychology, Autonomous University of Barcelona, Barcelona, Spain (Dr Soler)
| | - Luís Eduardo Luna
- School of Medicine, Autonomous University of Barcelona, Barcelona, Spain (Mr Sampedro); Human Neuropsychopharmacology Research Group, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr de la Fuente Revenga, Ms Roberto, and Dr Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr Valle); Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Drs Valle and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Elices, Álvarez, Soler, Pascual, and Riba); Department of Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain (Dr Valle); Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, Soler, and Pascual); Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, and Pascual); Research Center for the Study of Psychointegrator Plants, Visionary Art and Consciousness, Florianópolis, Santa Catarina, Brazil (Dr Luna); Department of Neuroscience and Behavior, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil and National Institute for Translational Medicine, Ribeirão Preto, Brazil (Drs Crippa and Hallak); Brain Institute/Hospital Universitario Onofre Lopes, Natal, Brazil (Dr de Araujo); The Beckley Foundation, Beckley Park, Oxford, United Kingdom (Mr Friedlander and Mrs Feilding); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, Louisiana (Dr Barker); Department of Clinical and Health Psychology, School of Psychology, Autonomous University of Barcelona, Barcelona, Spain (Dr Soler)
| | - José Alexandre S Crippa
- School of Medicine, Autonomous University of Barcelona, Barcelona, Spain (Mr Sampedro); Human Neuropsychopharmacology Research Group, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr de la Fuente Revenga, Ms Roberto, and Dr Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr Valle); Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Drs Valle and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Elices, Álvarez, Soler, Pascual, and Riba); Department of Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain (Dr Valle); Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, Soler, and Pascual); Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, and Pascual); Research Center for the Study of Psychointegrator Plants, Visionary Art and Consciousness, Florianópolis, Santa Catarina, Brazil (Dr Luna); Department of Neuroscience and Behavior, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil and National Institute for Translational Medicine, Ribeirão Preto, Brazil (Drs Crippa and Hallak); Brain Institute/Hospital Universitario Onofre Lopes, Natal, Brazil (Dr de Araujo); The Beckley Foundation, Beckley Park, Oxford, United Kingdom (Mr Friedlander and Mrs Feilding); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, Louisiana (Dr Barker); Department of Clinical and Health Psychology, School of Psychology, Autonomous University of Barcelona, Barcelona, Spain (Dr Soler)
| | - Jaime E C Hallak
- School of Medicine, Autonomous University of Barcelona, Barcelona, Spain (Mr Sampedro); Human Neuropsychopharmacology Research Group, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr de la Fuente Revenga, Ms Roberto, and Dr Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr Valle); Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Drs Valle and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Elices, Álvarez, Soler, Pascual, and Riba); Department of Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain (Dr Valle); Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, Soler, and Pascual); Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, and Pascual); Research Center for the Study of Psychointegrator Plants, Visionary Art and Consciousness, Florianópolis, Santa Catarina, Brazil (Dr Luna); Department of Neuroscience and Behavior, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil and National Institute for Translational Medicine, Ribeirão Preto, Brazil (Drs Crippa and Hallak); Brain Institute/Hospital Universitario Onofre Lopes, Natal, Brazil (Dr de Araujo); The Beckley Foundation, Beckley Park, Oxford, United Kingdom (Mr Friedlander and Mrs Feilding); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, Louisiana (Dr Barker); Department of Clinical and Health Psychology, School of Psychology, Autonomous University of Barcelona, Barcelona, Spain (Dr Soler)
| | - Draulio B de Araujo
- School of Medicine, Autonomous University of Barcelona, Barcelona, Spain (Mr Sampedro); Human Neuropsychopharmacology Research Group, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr de la Fuente Revenga, Ms Roberto, and Dr Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr Valle); Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Drs Valle and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Elices, Álvarez, Soler, Pascual, and Riba); Department of Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain (Dr Valle); Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, Soler, and Pascual); Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, and Pascual); Research Center for the Study of Psychointegrator Plants, Visionary Art and Consciousness, Florianópolis, Santa Catarina, Brazil (Dr Luna); Department of Neuroscience and Behavior, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil and National Institute for Translational Medicine, Ribeirão Preto, Brazil (Drs Crippa and Hallak); Brain Institute/Hospital Universitario Onofre Lopes, Natal, Brazil (Dr de Araujo); The Beckley Foundation, Beckley Park, Oxford, United Kingdom (Mr Friedlander and Mrs Feilding); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, Louisiana (Dr Barker); Department of Clinical and Health Psychology, School of Psychology, Autonomous University of Barcelona, Barcelona, Spain (Dr Soler)
| | - Pablo Friedlander
- School of Medicine, Autonomous University of Barcelona, Barcelona, Spain (Mr Sampedro); Human Neuropsychopharmacology Research Group, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr de la Fuente Revenga, Ms Roberto, and Dr Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr Valle); Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Drs Valle and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Elices, Álvarez, Soler, Pascual, and Riba); Department of Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain (Dr Valle); Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, Soler, and Pascual); Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, and Pascual); Research Center for the Study of Psychointegrator Plants, Visionary Art and Consciousness, Florianópolis, Santa Catarina, Brazil (Dr Luna); Department of Neuroscience and Behavior, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil and National Institute for Translational Medicine, Ribeirão Preto, Brazil (Drs Crippa and Hallak); Brain Institute/Hospital Universitario Onofre Lopes, Natal, Brazil (Dr de Araujo); The Beckley Foundation, Beckley Park, Oxford, United Kingdom (Mr Friedlander and Mrs Feilding); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, Louisiana (Dr Barker); Department of Clinical and Health Psychology, School of Psychology, Autonomous University of Barcelona, Barcelona, Spain (Dr Soler)
| | - Steven A Barker
- School of Medicine, Autonomous University of Barcelona, Barcelona, Spain (Mr Sampedro); Human Neuropsychopharmacology Research Group, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr de la Fuente Revenga, Ms Roberto, and Dr Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr Valle); Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Drs Valle and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Elices, Álvarez, Soler, Pascual, and Riba); Department of Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain (Dr Valle); Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, Soler, and Pascual); Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, and Pascual); Research Center for the Study of Psychointegrator Plants, Visionary Art and Consciousness, Florianópolis, Santa Catarina, Brazil (Dr Luna); Department of Neuroscience and Behavior, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil and National Institute for Translational Medicine, Ribeirão Preto, Brazil (Drs Crippa and Hallak); Brain Institute/Hospital Universitario Onofre Lopes, Natal, Brazil (Dr de Araujo); The Beckley Foundation, Beckley Park, Oxford, United Kingdom (Mr Friedlander and Mrs Feilding); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, Louisiana (Dr Barker); Department of Clinical and Health Psychology, School of Psychology, Autonomous University of Barcelona, Barcelona, Spain (Dr Soler)
| | - Enrique Álvarez
- School of Medicine, Autonomous University of Barcelona, Barcelona, Spain (Mr Sampedro); Human Neuropsychopharmacology Research Group, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr de la Fuente Revenga, Ms Roberto, and Dr Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr Valle); Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Drs Valle and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Elices, Álvarez, Soler, Pascual, and Riba); Department of Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain (Dr Valle); Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, Soler, and Pascual); Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, and Pascual); Research Center for the Study of Psychointegrator Plants, Visionary Art and Consciousness, Florianópolis, Santa Catarina, Brazil (Dr Luna); Department of Neuroscience and Behavior, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil and National Institute for Translational Medicine, Ribeirão Preto, Brazil (Drs Crippa and Hallak); Brain Institute/Hospital Universitario Onofre Lopes, Natal, Brazil (Dr de Araujo); The Beckley Foundation, Beckley Park, Oxford, United Kingdom (Mr Friedlander and Mrs Feilding); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, Louisiana (Dr Barker); Department of Clinical and Health Psychology, School of Psychology, Autonomous University of Barcelona, Barcelona, Spain (Dr Soler)
| | - Joaquim Soler
- School of Medicine, Autonomous University of Barcelona, Barcelona, Spain (Mr Sampedro); Human Neuropsychopharmacology Research Group, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr de la Fuente Revenga, Ms Roberto, and Dr Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr Valle); Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Drs Valle and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Elices, Álvarez, Soler, Pascual, and Riba); Department of Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain (Dr Valle); Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, Soler, and Pascual); Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, and Pascual); Research Center for the Study of Psychointegrator Plants, Visionary Art and Consciousness, Florianópolis, Santa Catarina, Brazil (Dr Luna); Department of Neuroscience and Behavior, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil and National Institute for Translational Medicine, Ribeirão Preto, Brazil (Drs Crippa and Hallak); Brain Institute/Hospital Universitario Onofre Lopes, Natal, Brazil (Dr de Araujo); The Beckley Foundation, Beckley Park, Oxford, United Kingdom (Mr Friedlander and Mrs Feilding); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, Louisiana (Dr Barker); Department of Clinical and Health Psychology, School of Psychology, Autonomous University of Barcelona, Barcelona, Spain (Dr Soler)
| | - Juan C Pascual
- School of Medicine, Autonomous University of Barcelona, Barcelona, Spain (Mr Sampedro); Human Neuropsychopharmacology Research Group, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr de la Fuente Revenga, Ms Roberto, and Dr Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr Valle); Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Drs Valle and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Elices, Álvarez, Soler, Pascual, and Riba); Department of Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain (Dr Valle); Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, Soler, and Pascual); Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, and Pascual); Research Center for the Study of Psychointegrator Plants, Visionary Art and Consciousness, Florianópolis, Santa Catarina, Brazil (Dr Luna); Department of Neuroscience and Behavior, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil and National Institute for Translational Medicine, Ribeirão Preto, Brazil (Drs Crippa and Hallak); Brain Institute/Hospital Universitario Onofre Lopes, Natal, Brazil (Dr de Araujo); The Beckley Foundation, Beckley Park, Oxford, United Kingdom (Mr Friedlander and Mrs Feilding); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, Louisiana (Dr Barker); Department of Clinical and Health Psychology, School of Psychology, Autonomous University of Barcelona, Barcelona, Spain (Dr Soler)
| | - Amanda Feilding
- School of Medicine, Autonomous University of Barcelona, Barcelona, Spain (Mr Sampedro); Human Neuropsychopharmacology Research Group, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr de la Fuente Revenga, Ms Roberto, and Dr Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr Valle); Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Drs Valle and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Elices, Álvarez, Soler, Pascual, and Riba); Department of Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain (Dr Valle); Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, Soler, and Pascual); Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, and Pascual); Research Center for the Study of Psychointegrator Plants, Visionary Art and Consciousness, Florianópolis, Santa Catarina, Brazil (Dr Luna); Department of Neuroscience and Behavior, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil and National Institute for Translational Medicine, Ribeirão Preto, Brazil (Drs Crippa and Hallak); Brain Institute/Hospital Universitario Onofre Lopes, Natal, Brazil (Dr de Araujo); The Beckley Foundation, Beckley Park, Oxford, United Kingdom (Mr Friedlander and Mrs Feilding); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, Louisiana (Dr Barker); Department of Clinical and Health Psychology, School of Psychology, Autonomous University of Barcelona, Barcelona, Spain (Dr Soler)
| | - Jordi Riba
- School of Medicine, Autonomous University of Barcelona, Barcelona, Spain (Mr Sampedro); Human Neuropsychopharmacology Research Group, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr de la Fuente Revenga, Ms Roberto, and Dr Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr Valle); Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Drs Valle and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Elices, Álvarez, Soler, Pascual, and Riba); Department of Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain (Dr Valle); Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, Soler, and Pascual); Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, and Pascual); Research Center for the Study of Psychointegrator Plants, Visionary Art and Consciousness, Florianópolis, Santa Catarina, Brazil (Dr Luna); Department of Neuroscience and Behavior, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil and National Institute for Translational Medicine, Ribeirão Preto, Brazil (Drs Crippa and Hallak); Brain Institute/Hospital Universitario Onofre Lopes, Natal, Brazil (Dr de Araujo); The Beckley Foundation, Beckley Park, Oxford, United Kingdom (Mr Friedlander and Mrs Feilding); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, Louisiana (Dr Barker); Department of Clinical and Health Psychology, School of Psychology, Autonomous University of Barcelona, Barcelona, Spain (Dr Soler)
| |
Collapse
|
25
|
Kuypers KPC, Riba J, de la Fuente Revenga M, Barker S, Theunissen EL, Ramaekers JG. Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. Psychopharmacology (Berl) 2016; 233:3395-403. [PMID: 27435062 PMCID: PMC4989012 DOI: 10.1007/s00213-016-4377-8] [Citation(s) in RCA: 119] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2016] [Accepted: 07/06/2016] [Indexed: 01/09/2023]
Abstract
INTRODUCTION Ayahuasca is a South American psychotropic plant tea traditionally used in Amazonian shamanism. The tea contains the psychedelic 5-HT2A receptor agonist N,N-dimethyltryptamine (DMT), plus β-carboline alkaloids with monoamine oxidase-inhibiting properties. Increasing evidence from anecdotal reports and open-label studies indicates that ayahuasca may have therapeutic effects in treatment of substance use disorders and depression. A recent study on the psychological effects of ayahuasca found that the tea reduces judgmental processing and inner reactivity, classic goals of mindfulness psychotherapy. Another psychological facet that could potentially be targeted by ayahuasca is creative divergent thinking. This mode of thinking can enhance and strengthen psychological flexibility by allowing individuals to generate new and effective cognitive, emotional, and behavioral strategies. The present study aimed to assess the potential effects of ayahuasca on creative thinking. METHODS We visited two spiritual ayahuasca workshops and invited participants to conduct creativity tests before and during the acute effects of ayahuasca. In total, 26 participants consented. Creativity tests included the "pattern/line meanings test" (PLMT) and the "picture concept test" (PCT), both assessing divergent thinking and the latter also assessing convergent thinking. RESULTS While no significant effects were found for the PLMT, ayahuasca intake significantly modified divergent and convergent thinking as measured by the PCT. While convergent thinking decreased after intake, divergent thinking increased. CONCLUSIONS The present data indicate that ayahuasca enhances creative divergent thinking. They suggest that ayahuasca increases psychological flexibility, which may facilitate psychotherapeutic interventions and support clinical trial initiatives.
Collapse
Affiliation(s)
- K P C Kuypers
- Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands.
| | - J Riba
- Human Experimental Neuropsychopharmacology, Sant Pau Institute of Biomedical Research, Barcelona, Spain
| | - M de la Fuente Revenga
- Human Experimental Neuropsychopharmacology, Sant Pau Institute of Biomedical Research, Barcelona, Spain
| | - S Barker
- Department of Comparative Biomedical Sciences, Louisiana State University, Baton Rouge, LA, USA
| | - E L Theunissen
- Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands
| | - J G Ramaekers
- Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands
| |
Collapse
|
26
|
Valle M, Maqueda AE, Rabella M, Rodríguez-Pujadas A, Antonijoan RM, Romero S, Alonso JF, Mañanas MÀ, Barker S, Friedlander P, Feilding A, Riba J. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. Eur Neuropsychopharmacol 2016; 26:1161-75. [PMID: 27039035 DOI: 10.1016/j.euroneuro.2016.03.012] [Citation(s) in RCA: 114] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2015] [Revised: 03/02/2016] [Accepted: 03/19/2016] [Indexed: 12/11/2022]
Abstract
Ayahuasca is an Amazonian psychotropic plant tea typically obtained from two plants, Banisteriopsis caapi and Psychotria viridis. It contains the psychedelic 5-HT2A and sigma-1 agonist N,N-dimethyltryptamine (DMT) plus β-carboline alkaloids with monoamine-oxidase (MAO)-inhibiting properties. Although the psychoactive effects of ayahuasca have commonly been attributed solely to agonism at the 5-HT2A receptor, the molecular target of classical psychedelics, this has not been tested experimentally. Here we wished to study the contribution of the 5-HT2A receptor to the neurophysiological and psychological effects of ayahuasca in humans. We measured drug-induced changes in spontaneous brain oscillations and subjective effects in a double-blind randomized placebo-controlled study involving the oral administration of ayahuasca (0.75mg DMT/kg body weight) and the 5-HT2A antagonist ketanserin (40mg). Twelve healthy, experienced psychedelic users (5 females) participated in four experimental sessions in which they received the following drug combinations: placebo+placebo, placebo+ayahuasca, ketanserin+placebo and ketanserin+ayahuasca. Ayahuasca induced EEG power decreases in the delta, theta and alpha frequency bands. Current density in alpha-band oscillations in parietal and occipital cortex was inversely correlated with the intensity of visual imagery induced by ayahuasca. Pretreatment with ketanserin inhibited neurophysiological modifications, reduced the correlation between alpha and visual effects, and attenuated the intensity of the subjective experience. These findings suggest that despite the chemical complexity of ayahuasca, 5-HT2A activation plays a key role in the neurophysiological and visual effects of ayahuasca in humans.
Collapse
Affiliation(s)
- Marta Valle
- Pharmacokinetic and Pharmacodynamic Modelling and Simulation, IIB Sant Pau, Sant Antoni María Claret, 167, 08025 Barcelona, Spain; Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Sant Antoni María Claret, 167, 08025 Barcelona, Spain; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain
| | - Ana Elda Maqueda
- Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; Human Neuropsychopharmacology Research Group. Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, 167, 08025 Barcelona, Spain
| | - Mireia Rabella
- Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; Servei de Psiquiatria, Hospital de la Santa Creu i Sant Pau, Sant Antoni María Claret, 167, 08025 Barcelona, Spain
| | - Aina Rodríguez-Pujadas
- Human Neuropsychopharmacology Research Group. Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, 167, 08025 Barcelona, Spain
| | - Rosa Maria Antonijoan
- Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Sant Antoni María Claret, 167, 08025 Barcelona, Spain; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain
| | - Sergio Romero
- Biomedical Engineering Research Centre (CREB), Department of Automatic Control (ESAII), Universitat Politècnica de Catalunya (UPC), Barcelona, Spain; CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain
| | - Joan Francesc Alonso
- Biomedical Engineering Research Centre (CREB), Department of Automatic Control (ESAII), Universitat Politècnica de Catalunya (UPC), Barcelona, Spain; CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain; Barcelona College of Industrial Engineering (EUETIB), UniversitatPolitècnica de Catalunya (UPC), Barcelona 08028, Spain
| | - Miquel Àngel Mañanas
- Biomedical Engineering Research Centre (CREB), Department of Automatic Control (ESAII), Universitat Politècnica de Catalunya (UPC), Barcelona, Spain; CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain; Barcelona College of Industrial Engineering (EUETIB), UniversitatPolitècnica de Catalunya (UPC), Barcelona 08028, Spain
| | - Steven Barker
- Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA 70803, USA
| | - Pablo Friedlander
- The Beckley Foundation, Beckley Park, Oxford OX3 9SY, United Kingdom
| | - Amanda Feilding
- The Beckley Foundation, Beckley Park, Oxford OX3 9SY, United Kingdom
| | - Jordi Riba
- Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Sant Antoni María Claret, 167, 08025 Barcelona, Spain; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain; Human Neuropsychopharmacology Research Group. Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, 167, 08025 Barcelona, Spain.
| |
Collapse
|
27
|
Lesiak AD, Musah RA. Application of ambient ionization high resolution mass spectrometry to determination of the botanical provenance of the constituents of psychoactive drug mixtures. Forensic Sci Int 2016; 266:271-280. [PMID: 27348465 DOI: 10.1016/j.forsciint.2016.06.009] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2016] [Revised: 05/21/2016] [Accepted: 06/07/2016] [Indexed: 11/26/2022]
Abstract
A continuing challenge in analytical chemistry is species-level determination of the constituents of mixtures that are made of a combination of plant species. There is an added urgency to identify components in botanical mixtures that have mind altering properties, due to the increasing global abuse of combinations of such plants. Here we demonstrate the proof of principle that ambient ionization mass spectrometry, namely direct analysis in real time-high resolution mass spectrometry (DART-HRMS), and statistical analysis tools can be used to rapidly determine the individual components within a psychoactive brew (Ayahuasca) made from a mixture of botanicals. Five plant species used in Ayahuasca preparations were subjected to DART-HRMS analysis. The chemical fingerprint of each was reproducible but unique, thus enabling discrimination between them. The presence of important biomarkers, including N,N-dimethyltryptamine, harmaline and harmine, was confirmed using in-source collision-induced dissociation (CID). Six Ayahuasca brews made from combinations of various plant species were shown to possess a high level of similarity, despite having been made from different constituents. Nevertheless, the application of principal component analysis (PCA) was useful in distinguishing between each of the brews based on the botanical species used in the preparations. From a training set based on 900 individual analyses, three principal components covered 86.38% of the variance, and the leave-one-out cross validation was 98.88%. This is the first report of ambient ionization MS being successfully used for determination of the individual components of plant mixtures.
Collapse
Affiliation(s)
- Ashton D Lesiak
- Department of Chemistry, University at Albany-State University of New York, 1400 Washington Ave, Albany, NY 12222, United States
| | - Rabi A Musah
- Department of Chemistry, University at Albany-State University of New York, 1400 Washington Ave, Albany, NY 12222, United States.
| |
Collapse
|
28
|
Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities. Psychopharmacology (Berl) 2016; 233:823-9. [PMID: 26612618 DOI: 10.1007/s00213-015-4162-0] [Citation(s) in RCA: 112] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/21/2015] [Accepted: 11/15/2015] [Indexed: 12/24/2022]
Abstract
BACKGROUND Ayahuasca is a psychotropic plant tea used for ritual purposes by the indigenous populations of the Amazon. In the last two decades, its use has expanded worldwide. The tea contains the psychedelic 5-HT2A receptor agonist N,N-dimethyltryptamine (DMT), plus β-carboline alkaloids with monoamine-oxidase-inhibiting properties. Acute administration induces an introspective dream-like experience characterized by visions and autobiographic and emotional memories. Studies of long-term users have suggested its therapeutic potential, reporting that its use has helped individuals abandon the consumption of addictive drugs. Furthermore, recent open-label studies in patients with treatment-resistant depression found that a single ayahuasca dose induced a rapid antidepressant effect that was maintained weeks after administration. Here, we conducted an exploratory study of the psychological mechanisms that could underlie the beneficial effects of ayahuasca. METHODS We assessed a group of 25 individuals before and 24 h after an ayahuasca session using two instruments designed to measure mindfulness capacities: The Five Facets Mindfulness Questionnaire (FFMQ) and the Experiences Questionnaire (EQ). RESULTS Ayahuasca intake led to significant increases in two facets of the FFMQ indicating a reduction in judgmental processing of experiences and in inner reactivity. It also led to a significant increase in decentering ability as measured by the EQ. These changes are classic goals of conventional mindfulness training, and the scores obtained are in the range of those observed after extensive mindfulness practice. CONCLUSIONS The present findings support the claim that ayahuasca has therapeutic potential and suggest that this potential is due to an increase in mindfulness capacities.
Collapse
|
29
|
Temerdashev AZ, Grigoriev AM, Rybalchenko IV. Narcotic substances of natural origin and methods of their determination. JOURNAL OF ANALYTICAL CHEMISTRY 2015. [DOI: 10.1134/s1061934816010135] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
30
|
Schenberg EE, Alexandre JFM, Filev R, Cravo AM, Sato JR, Muthukumaraswamy SD, Yonamine M, Waguespack M, Lomnicka I, Barker SA, da Silveira DX. Acute Biphasic Effects of Ayahuasca. PLoS One 2015; 10:e0137202. [PMID: 26421727 PMCID: PMC4589238 DOI: 10.1371/journal.pone.0137202] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2015] [Accepted: 08/13/2015] [Indexed: 12/14/2022] Open
Abstract
Ritual use of ayahuasca, an amazonian Amerindian medicine turned sacrament in syncretic religions in Brazil, is rapidly growing around the world. Because of this internationalization, a comprehensive understanding of the pharmacological mechanisms of action of the brew and the neural correlates of the modified states of consciousness it induces is important. Employing a combination of electroencephalogram (EEG) recordings and quantification of ayahuasca's compounds and their metabolites in the systemic circulation we found ayahuasca to induce a biphasic effect in the brain. This effect was composed of reduced power in the alpha band (8-13 Hz) after 50 minutes from ingestion of the brew and increased slow- and fast-gamma power (30-50 and 50-100 Hz, respectively) between 75 and 125 minutes. Alpha power reductions were mostly located at left parieto-occipital cortex, slow-gamma power increase was observed at left centro-parieto-occipital, left fronto-temporal and right frontal cortices while fast-gamma increases were significant at left centro-parieto-occipital, left fronto-temporal, right frontal and right parieto-occipital cortices. These effects were significantly associated with circulating levels of ayahuasca's chemical compounds, mostly N,N-dimethyltryptamine (DMT), harmine, harmaline and tetrahydroharmine and some of their metabolites. An interpretation based on a cognitive and emotional framework relevant to the ritual use of ayahuasca, as well as it's potential therapeutic effects is offered.
Collapse
Affiliation(s)
| | | | - Renato Filev
- Departamento de Psiquiatria, Universidade Federal de São Paulo, São Paulo, Brazil
| | - Andre Mascioli Cravo
- Centro de Matemática, Computação e Cognição, Universidade Federal do ABC, Santo André, Brazil
| | - João Ricardo Sato
- Centro de Matemática, Computação e Cognição, Universidade Federal do ABC, Santo André, Brazil
| | | | - Maurício Yonamine
- Departamento de Análises Clinicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, Brazil
| | - Marian Waguespack
- Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, United States of America
| | - Izabela Lomnicka
- Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, United States of America
| | - Steven A. Barker
- Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, United States of America
| | | |
Collapse
|
31
|
Queiroz MMF, Queiroz EF, Zeraik ML, Ebrahimi SN, Marcourt L, Cuendet M, Castro-Gamboa I, Hamburger M, da Silva Bolzani V, Wolfender JL. Chemical composition of the bark of Tetrapterys mucronata and identification of acetylcholinesterase inhibitory constituents. JOURNAL OF NATURAL PRODUCTS 2014; 77:650-656. [PMID: 24521095 DOI: 10.1021/np401003p] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
The secondary metabolite content of Tetrapterys mucronata, a poorly studied plant that is used occasionally in Brazil for the preparation of a psychotropic plant decoction called "Ayahuasca", was determined to establish its chemical composition and to search for acetylcholinesterase (AChE) inhibitors. The ethanolic extract of the bark of T. mucronata exhibited in vitro AChE inhibition in a TLC bioautography assay. To localize the active compounds, biological profiling for AChE inhibition was performed using at-line HPLC-microfractionation in 96-well plates and subsequent AChE inhibition bioautography. The analytical HPLC-PDA conditions were transferred geometrically to a preparative medium-pressure liquid chromatography column using chromatographic calculations for the efficient isolation of the active compounds at the milligram scale. Twenty-two compounds were isolated, of which six are new natural products. The structures of the new compounds (9, 10, 16-18, and 20) were elucidated by spectroscopic data interpretation. Compounds 1, 5, 6, 9, and 10 inhibited AChE with IC50 values below 15 μM.
Collapse
Affiliation(s)
- Marcos Marçal Ferreira Queiroz
- Núcleo de Bioensaios, Biossíntese e Ecofisiologia de Produtos Naturais, NuBBE, Instituto de Química, Universidade Estadual Paulista (UNESP) , Araraquara, São Paulo, Brazil
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Posch TN, Martin N, Pütz M, Huhn C. Nonaqueous capillary electrophoresis-mass spectrometry: a versatile, straightforward tool for the analysis of alkaloids from psychoactive plant extracts. Electrophoresis 2012; 33:1557-66. [PMID: 22736357 DOI: 10.1002/elps.201100682] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
In this study we show that a nonaqueous capillary electrophoresis mass spectrometry (NACE-MS) method carefully optimized by a design of experiment can be applied to a very large number of alkaloids in different plant extracts. It is possible to characterize the pattern of the psychoactive alkaloids in several plant samples and preparations thereof, each presenting different challenges in their analysis. The method is shown to be able to separate structurally closely related substances, diastereomers and further isobaric compounds, to separate members of different alkaloid classes within one run and to tolerate significant matrix load. A comparison with methods presented in the literature reveals that a near-generic NACE-MS method for the fast profiling of alkaloids in forensically relevant plant samples has been developed.
Collapse
Affiliation(s)
- Tjorben Nils Posch
- Forschungszentrum Jülich GmbH, Central Division of Analytical Chemistry, Jülich, Germany
| | | | | | | |
Collapse
|
33
|
Ivanova B, Spiteller M. Quantitative Analysis of Substituted N,N-Dimethyl-tryptamines in the Presence of Natural Type XII Alkaloids. Nat Prod Commun 2012. [DOI: 10.1177/1934578x1200701006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
This paper reports the qualitative and quantitative analysis (QA) of mixtures of hallucinogens, N,N-dimethyltryptamine (DMT) (1), 5-methoxy- (1a) and 5-hydroxy- N,N-dimethyltryptamine (1b) in the presence of β-carbolines (indole alkaloids of type XII) {(2), (3) and (5)}. The validated electronic absorption spectroscopic (EAs) protocol achieved a concentration limit of detection (LOD) of 7.2.10-7 mol/L {concentration limit of quantification (LOQ) of 24.10-7mol/L} using bands (λmax) within 260±0.23-262±0.33 nm. Metrology, including accuracy, measurement repeatability, measurement precision, trueness of measurement,and reproducibility of the measurements are presented using N,N- dimethyltryptamine (DMA) as standard. The analytical quantities of mixtures of alkaloids 4, 6 and 7 are: λmax 317±0.45, 338±0.69 and 430±0.09 for 4 (LOD, 8.6.10-7 mol/L; LOQ, 28.666, mol/L), as well as 528±0.75 nm for 6 and 7 (LOD, 8.2. 10-7 mol/L; LOQ, 27.333, mol/L), respectively. The partially validated protocols by high performance liquid chromatography (HPLC), electrospray ionization (ESI), mass spectrometry (MS), both in single and tandem operation (MS/MS) mode, as well as matrix/assisted laser desorption/ionization (MALDI) MS are elaborated. The Raman spectroscopic (RS) protocol for analysis of psychoactive substances, characterized by strong fluorescence RS profile was developed, with the detection limits being discussed. The known synergistic effect leading to increase the psychoactive and hallucinogenic properties and the reported acute poisoning cases from 1-7, make the present study emergent, since as well the current lack of analytical data and the herein metrology obtained contributed to the elaboration of highly selective and precise analytical protocols, which would be of interest in the field of criminal forensic analysis.
Collapse
Affiliation(s)
- Bojidarka Ivanova
- Institute of Environmental Research, Department of Environmental Chemistry and Analytical Chemistry, University of Dortmund, Otto–Hahn-Strasse 6, 44221 Dortmund, Germany
| | - Michael Spiteller
- Institute of Environmental Research, Department of Environmental Chemistry and Analytical Chemistry, University of Dortmund, Otto–Hahn-Strasse 6, 44221 Dortmund, Germany
| |
Collapse
|
34
|
Barbosa PCR, Mizumoto S, Bogenschutz MP, Strassman RJ. Health status of ayahuasca users. Drug Test Anal 2012; 4:601-9. [DOI: 10.1002/dta.1383] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2012] [Revised: 05/15/2012] [Accepted: 05/15/2012] [Indexed: 11/09/2022]
|
35
|
Gaujac A, Navickiene S, Collins MI, Brandt SD, Andrade JB. Analytical techniques for the determination of tryptamines and β-carbolines in plant matrices and in psychoactive beverages consumed during religious ceremonies and neo-shamanic urban practices. Drug Test Anal 2012; 4:636-48. [DOI: 10.1002/dta.1343] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2011] [Revised: 02/23/2012] [Accepted: 02/23/2012] [Indexed: 11/09/2022]
Affiliation(s)
| | - Sandro Navickiene
- Universidade Federal de Sergipe (UFS); Campus São Cristóvão; São Cristóvão-; Se; Brazil
| | - Mark I. Collins
- Universidade Estadual do Ceará (UECE); Campus do Itaperi; Fortaleza-; Ce; Brazil
| | - Simon D. Brandt
- Liverpool John Moores University; School of Pharmacy and Biomolecular Sciences; Liverpool; UK
| | | |
Collapse
|
36
|
Gaujac A, Aquino A, Navickiene S, de Andrade JB. Determination of N,N-dimethyltryptamine in Mimosa tenuiflora inner barks by matrix solid-phase dispersion procedure and GC–MS. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 881-882:107-10. [DOI: 10.1016/j.jchromb.2011.11.014] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2011] [Revised: 11/04/2011] [Accepted: 11/05/2011] [Indexed: 11/17/2022]
|
37
|
Mol H, Van Dam R, Zomer P, Mulder P. Screening of plant toxins in food, feed and botanicals using full-scan high-resolution (Orbitrap) mass spectrometry. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2011; 28:1405-23. [DOI: 10.1080/19440049.2011.603704] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
38
|
McIlhenny EH, Riba J, Barbanoj MJ, Strassman R, Barker SA. Methodology for determining major constituents of ayahuasca and their metabolites in blood. Biomed Chromatogr 2011; 26:301-13. [PMID: 21710581 DOI: 10.1002/bmc.1657] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2011] [Revised: 04/06/2011] [Accepted: 04/18/2011] [Indexed: 11/11/2022]
Abstract
There is an increasing interest in potential medical applications of ayahuasca, a South American psychotropic plant tea with a long cultural history of indigenous medical and religious use. Clinical research into ayahuasca will require specific, sensitive and comprehensive methods for the characterization and quantitation of these compounds and their metabolites in blood. A combination of two analytical techniques (high-performance liquid chromatography with ultraviolet and/or fluorescence detection and gas chromatography with nitrogen-phosphorus detection) has been used for the analysis of some of the constituents of ayahuasca in blood following its oral consumption. We report here a single methodology for the direct analysis of 14 of the major alkaloid components of ayahuasca, including several known and potential metabolites of N,N-dimethyltryptamine and the harmala alkaloids in blood. The method uses 96-well plate/protein precipitation/filtration for plasma samples, and analysis by HPLC-ion trap-ion trap-mass spectrometry using heated electrospray ionization to reduce matrix effects. The method expands the list of compounds capable of being monitored in blood following ayahuasca administration while providing a simplified approach to their analysis. The method has adequate sensitivity, specificity and reproducibility to make it useful for clinical research with ayahuasca.
Collapse
Affiliation(s)
- Ethan H McIlhenny
- Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70806, USA
| | | | | | | | | |
Collapse
|
39
|
Labate BC, Cavnar C. The expansion of the field of research on ayahuasca: Some reflections about the ayahuasca track at the 2010 MAPS “Psychedelic Science in the 21st Century” conference. THE INTERNATIONAL JOURNAL OF DRUG POLICY 2011; 22:174-8. [DOI: 10.1016/j.drugpo.2010.09.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2010] [Revised: 08/02/2010] [Accepted: 09/02/2010] [Indexed: 11/30/2022]
|
40
|
Microwave-accelerated preparation and analytical characterization of 5-ethoxy-N,N-dialkyl-[α,α,β,β-H4]- and [α,α,β,β-D4]-tryptamines. Drug Test Anal 2010; 3:597-608. [DOI: 10.1002/dta.223] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2010] [Accepted: 10/08/2010] [Indexed: 11/07/2022]
|
41
|
dos Santos RG. Toxicity of chronic ayahuasca administration to the pregnant rat: how relevant it is regarding the human, ritual use of ayahuasca? ACTA ACUST UNITED AC 2010; 89:533-5; author reply 531-2.. [DOI: 10.1002/bdrb.20272] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
42
|
McIlhenny EH, Riba J, Barbanoj MJ, Strassman R, Barker SA. Methodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human urine. Biomed Chromatogr 2010; 25:970-84. [PMID: 21058415 DOI: 10.1002/bmc.1551] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2010] [Revised: 09/10/2010] [Accepted: 09/14/2010] [Indexed: 11/07/2022]
Abstract
Ayahuasca, also known as caapi or yage among various South American groups, holds a highly esteemed and millennia-old position in these cultures' medical and religious pharmacopeia. There is now an increasing interest in the potential for modern medical applications of ayahuasca, as well as concerns regarding its increasing potential for abuse. Toxicological and clinical research to address these issues will require information regarding its metabolism and clearance. Thus, a rapid, sensitive and specific method for characterization and quantitation of the major constituents and of the metabolites of ayahuasca in urine is needed. The present research provides a protocol for conducting such analyses. The characteristics of the method, conducted by sample dilution and using HPLC-electrospray ionization (ESI)-selected reaction monitoring (SRM)-tandem mass spectrometry, are presented. The application of the analytical protocol to urine samples collected from three individuals that were administered ayahuasca has also been demonstrated. The data show that the major metabolite of the hallucinogenic component of ayahuasca, N,N-dimethyltryptamine (DMT), is the corresponding N-oxide, the first time this metabolite has been described in in vivo studies in humans. Further, very little DMT was detected in urine, despite the inhibition of monoamine oxidase afforded by the presence of the harmala alkaloids in ayahuasca. The major harmala alkaloid excreted was tetrahydroharmine. Other excretion products and metabolites were also identified and quantified. The method described would be suitable for use in further toxicological and clinical research on ayahuasca.
Collapse
Affiliation(s)
- Ethan H McIlhenny
- Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA
| | | | | | | | | |
Collapse
|
43
|
Determination of anthelmintic drug residues in milk using ultra high performance liquid chromatography–tandem mass spectrometry with rapid polarity switching. J Chromatogr A 2010; 1217:4612-22. [DOI: 10.1016/j.chroma.2010.05.007] [Citation(s) in RCA: 126] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
44
|
Current Awareness in Drug Testing and Analysis. Drug Test Anal 2010. [DOI: 10.1002/dta.63] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|